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THESIS ABSTRACT 
 
Background 
Medication error is an important patient safety issue worldwide and results in morbidity, mortality 
and economic burden. The true cost of medication error is unclear from current evidence.  
Medication error is particularly common at the primary secondary care interface as patients move 
between hospital and the community. Developing interventions to reduce medication error (and in 
particular error at this interface in care) is currently an international priority. Existing interventions, 
such as medication reconciliation, are often resource intensive.  Within healthcare systems, where 
resources are limited, measures to reduce costs and improve process efficiency are required in 
addition to optimising patient care.  
Aim 
The overarching aim of this thesis is to examine medication error at the primary secondary care 
interface in terms of cost, causes and consequences in order to develop a pragmatic intervention to 
facilitate its reduction.   
Structure and methods 
The Medical Research Council, UK (MRC) guidance on the development and evaluation of complex 
interventions in healthcare was employed.  
Existing evidence on the cost of medication error was systematically reviewed and synthesised in a 
narrative synthesis. A cost per error was extracted and expressed in Euro.   
A cross-sectional study was conducted. The study examined an existing process of medication 
reconciliation in terms of factors predicting time burden and associated financial cost. Logistic 
regression was used to investigate associations between patient characteristics and clinically 
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significant errors and additional time.  Cost for additional time was calculated in terms of hospital 
pharmacist salary.    
The new evidence generated was used, along with the existing evidence base, to develop a novel 
intervention aiming to reduce the occurrence of medication error at the primary secondary care 
interface. The intervention, the PHARMS (Patient Held Active Record of Medication Status) device, is 
a patient held electronic record used to transmit medication information between primary and 
secondary care.  
The intervention was evaluated by a mixed methods feasibility study (non-randomised controlled 
intervention and a process evaluation of qualitative interviews and non-participant observation). 
The study was informed by the Consolidated Framework for Implementation Research (CFIR). The 
occurrence of medication error was compared between groups and factors associated with 
medication error investigated using negative binomial regression. Thematic analysis of data from 
semi-structured interviews with key stakeholders was conducted.  
Results 
Systematic review: 16 studies were included in the systematic review. The review identified that 
medication error is associated with significant economic impact with an associated cost of up to 
€111,727.08 per error. In view of the limited parameters used to establish economic impact, it was 
concluded that the true economic burden of medication error may have been underestimated to 
date.  
Cross-sectional study: 89 patients were included. Having a personal record of medication at 
admission (OR 3.30, 95% CI: (1.05 to 10.42), p=0.004) was a significant predictor of additional time. 
No significant associations were found between the occurrence of clinically significant error and 
additional time (p>0.05). The most common reason for additional time was clarifying issues 
19 
 
pertaining to communication of medication information from primary care. Projected annual five 
year costs for the mean additional time of 3.75 minutes of the study were €1.8-1.9 million.  
Feasibility study: 102 patients were included (Intervention n=41, Control n=63). Total error number 
was lower in the intervention group Median=1 (0,3 IQR) than the control group Median=8 (4,13.5 
IQR) p <0.001, with the clinical significance score in the intervention group Median= 2 (IQR 0,4) also 
being lower than the control group Median=11 (IQR 5,20) p <0.001. The device was found to be 
technically implementable using existing IT infrastructure and acceptable to all key stakeholders. 
 
 Conclusion 
Medication error is a costly problem, the true extent of which may have been underestimated. 
Issues pertaining to communication of medication information at the primary secondary care 
interface were identified as contributing to the economic burden associated with medication 
reconciliation. In addition, it was identified that increasing time for medication reconciliation may 
not necessarily result cost savings in terms of reducing medication error. The intervention developed 
as a result of this thesis may have the potential to facilitate more efficient medication reconciliation 
and reduce medication error at the interface of primary and secondary care. This may result in both 
clinical and economic benefit.  
 
Limitations 
The overall numbers of patients included in the cross-sectional and feasibility studies in this thesis 
are small. In addition, these studies included only older adult patients in a single geographical 
location and involved a single hospital.  
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1. INTRODUCTION 
 
Medication error is the single most preventable cause of patient harm worldwide (1, 2).  Medication 
error frequently occurs as patients transition between primary and secondary care and is particularly 
common among older adult patients (3-7). The impact of such error at the primary secondary care 
interface ranges from process inefficiency in primary and secondary care to significant patient 
morbidity, mortality and economic burden (8). With a growing aging population worldwide, overall 
healthcare utilisation is increasing (9).  The occurrence of medication error at the primary secondary 
care interface places an additional burden on healthcare systems already struggling to meet current 
demands. Establishing effective methods to reduce medication error  at this interface in care is 
currently an international priority (2). Within the Irish healthcare system resources are limited (10). 
Measures to reduce costs and improve process efficiency are required in addition to optimising 
patient care. Examining medication error at the primary secondary care interface in terms of cost, 
causes and consequences is essential for the development of pragmatic effective methods to 
successfully address this important patient safety issue.   
 
 In the following review of the literature international evidence is presented initially in each section, 
followed by Irish evidence where available.  In the absence of Irish evidence, international evidence, 
as it applies to the Irish context, is discussed.  
 
1.1 Medication error 
 
The medication use process involves a number of steps namely; prescribing, transcribing, dispensing, 
administration and monitoring of medication.  Medication error is defined as a mistake occurring at 
any point during the medication use process (8). Medication may be associated with unavoidable 
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patient harm in the absence of error when adverse drug events (ADEs) arise due to medication side-
effects. Though not all medication errors result in harm, the ADEs associated with medication error 
are preventable however, and hence the associated harm is avoidable.  Reduction of medication 
error is currently an international priority with the World Health Organisation (WHO) stating their 
intent to “reduce the level of severe avoidable harm related to medications by 50% over 5 years 
globally” in 2017 (2). The United States Institute of Medicine’s landmark report  in 1999 “To Err is 
Human: Building a safer Health System” first highlighted the association of error in the healthcare 
system with patient morbidity and mortality and noted medication errors to be a major cause of 
iatrogenic harm (1). ADEs are reported to account for between 6.5% and 24% of acute hospital 
admissions with more than half the ADEs, being attributable to medication error (11-15).  
 
The reported prevalence of medication errors among patients in primary and secondary care varies 
from approximately 6% (16, 17) to 91% (17, 18). Multimorbidity (the presence of two or more 
chronic conditions) (19) and polypharmacy (the co-prescribing of five or more medications) (20) 
have been identified as risk factors for medication error. A greater prevalence of medication error 
has been reported in multimorbid patients and those taking multiple medications (18, 21, 22) (23-
27) and this is of particular relevance in relation to the aging populations in Ireland (and worldwide) 
who are more susceptible to these issues. Medication error has been identified as a major issue in 
the Irish context (28). A national clinical incident five-year review from 2010 to 2014 in Ireland found 
that medication errors accounted for 14.7% of the ten most commonly reported incidents and 
account for approximately 10% of adverse clinical incidents occurring nationally in older adult 
patients (29).  In addition, medication error accounts for up to one quarter of litigation claims 
against Irish GPs (30).  
 
The consequences of medication error are ADEs, drug-drug interactions, lack of efficacy, suboptimal 
patient adherence and experience and poor quality of life. In turn, these may have significant health 
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and economic consequences, including the increased use of health services, preventable 
medication-related hospital admissions and death (8, 31). The estimated cost of a preventable ADE 
(pADE) was calculated at USD $4,800 per event in a landmark study conducted by Bates et al in 1995 
(32), with costs as high as $10,375 per pADE subsequently being reported (33, 34). A review 
published in 2018 estimates costs of pADEs in the National Health Services (NHS), UK as £98.5 
million per year, consuming 181,626 bed-days, causing 712 deaths and contributing to 1,708 deaths. 
The costs of primary care pADEs are estimated to be £83.7 million; causing 627 deaths and 
secondary care pADEs to be £14.8 million; causing 85 deaths and contributing to 1,081 deaths (18). 
There is currently a lack of evidence regarding cost of medication error in the Irish context. The 
physical and psychological consequences for patients as a result of medication errors,  in addition to 
decreased patient satisfaction and lack of trust in the healthcare system, also contribute to 
economic burden (35). 
 
Prescribing error is thought to be the most significant form of medication error with over half of 
medication errors resulting in ADEs occurring at the prescribing  stage (31) (36). Inappropriate 
prescribing refers to the use of a drug where the risk of an adverse event outweighs the clinical 
benefit, particularly if a safer or more effective alternative therapy is available. Potentially 
inappropriate prescribing refers to such inappropriate prescribing as identified by standardised tools 
such as Beer’s criteria and STOPP/START (37). The prescribing of potentially inappropriate 
medications does necessarily represent prescribing error however. The possibility exists of an 
intentional and informed decision on the part of the prescriber to prescribe a high risk medication.  
 Estimated prevalence of prescribing error in secondary care ranges from 8% to 31% (38-40). Figures 
of between 45 and 57% of prescribing errors detected in the hospital setting have been reported as 
having the potential to cause patient harm (41-43).  Multiple perceived causes for prescribing error 
in the hospital context have been identified and include knowledge deficits among junior doctors, 
time pressure and poor communication and documentation of medication information (40, 44, 45). 
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Prescribing error is also prevalent in primary care (46-48). Prescribing error rates of between 1 and 
90 per 100 prescriptions issued have been described (48). Up to 72 % of prescribing errors occurring in 
the primary care setting have been reported as having the potential to cause patient harm (49). 
Prescribing error occurring in primary care has also been attributed to time pressure and workload. 
In addition problems with the timeliness, legibility, content, and layout of secondary care 
correspondence have been cited as contributory factors (47).  
Up to 50% of medication errors occur during transitions of care (3, 50) and such errors frequently 
occur among older adult patients (51, 52). Transitions of care are defined as “the various points 
where a patient moves to, or returns from, a particular physical location or makes contact with a 
health care professional for the purposes of receiving health care” and includes transitions between 
home, hospital, residential care settings and consultations with different health care providers in 
out-patient facilities (53). The primary secondary interface has been identified as a particular care 
transition where medication error is likely to occur (54-56) and incorrect medication information at 
this interface has been noted to be a major source of medication error in the Irish context (29). 
Reduction of medication error at the transitions of care has been  highlighted as a key objective both  
nationally by the Health Information Quality Authority (HIQA) and internationally by the WHO (8, 
57).  
Broadly defined as any mistake in the prescribing, dispensing, or administration of a drug, definitions 
for medication error vary in the literature with no one standard definition being applied universally 
(58-60). A recent systematic review has highlighted the need for uniform terminology improve 
communication between key stakeholders namely patients, clinicians, healthcare professionals, 
researchers, and policy makers to successfully address the problem of medication error (60). In 
response to the issues surrounding terminology the European Medicines Agency (EMA) produced a 
guide to promote a common approach to recording, coding, reporting and assessment of medication 
errors (61).  The EMA defines medication error as “an unintended failure in the drug treatment 
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process that leads to, or has the potential to lead to, harm to the patient”, specifying that a failure in 
the drug treatment process does not refer to lack of efficacy of the drug, rather to human or process 
mediated failures (62). This definition is used throughout the thesis.  
 
Medication errors can be classified in a number of different ways (63).  Errors can be classified 
according to stage of occurrence in the medication use process namely prescribing, transcribing, 
dispensing administration and monitoring. Another approach classifies errors according to mistakes 
made in either the planning or action stage of medication use (knowledge or action based errors). A 
further approach to classification uses the types of error such as wrong dose, route or frequency (8, 
18, 63).  The classification systems for medication error are not mutually exclusive and no evidence 
base currently exists for using a single system. The WHO states that classification selection is 
dependent on purpose and setting (8).  
In terms of implications for patient safety and practice establishing the clinical significance or level of 
harm associated with medication errors is required. Errors may however be captured in advance of 
reaching the patient or the clinical outcome of the error may be unknown. Hence establishing 
clinical significance of medication errors may require subjective judgement. The method described 
by Dean et al is a validated and reliable method using the judgement of healthcare professionals in 
the absence of knowledge of patient outcomes (64).  Systems to classify the clinical significance of 
medication errors vary in the literature. The EMA classification classifies errors as; (i) potential 
errors, (ii) intercepted errors, (iii) errors without harm and (iv) errors with harm (61).  Nesbit et al 
assign a probability of a harm occurring due to an ADE on a five point scale ranging from; no harm to 
high (65, 66). The Hartwig Severity assessment scale rates the severity of ADEs on a seven point scale 
ranging from; no change required to the drug treatment in question, to death (67). The National 
Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) taxonomy of 
medication errors classifies errors as causing no harm, harm, or death. It further rates errors, causing 
harm, on a four point scale from;  temporary harm requiring intervention, to intervention required  
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to sustain life (68). Bates et al classify medication errors as significant (little or no threat to the 
patient’s life function), serious (associated with a serious level of risk that is not high enough to be 
life-threatening) or life-threatening (error that if not treated would put the patient at risk of death) 
(32, 69). This classification system was recently used by Pevnick et al to calculate a novel error score 
for individual patients to quantify clinical significance.  Error severity weights of 12=1 (significant), 
22=4 (serious) and 32=9 (life-threatening), respectively, are assigned to reflect the relative capacity of 
each error type to cause patient harm and a summation of scores used to calculate the final score 
for an individual patient (70). The EMA classification system (61) is used in this thesis (Chapter 2) 
with the classification system of Pevnick et al (70) used to assign clinical significance of medication 
error (Chapters 3 and 5).   
 
1.2 Primary and secondary care in Ireland 
 
1.2.1 Structure 
 
 The Irish healthcare system has been described as a two tier system providing both public and 
private care. The General Medical Services (GMS) is a public system covering primary and secondary 
care costs for approximately 46% of patients in Ireland, with 46% of patients currently paying for 
private health insurance to cover potential costs of secondary care (71).  
Primary care for citizens in Ireland has been defined as “first level contact that is fully accessible by 
self-referral and has a strong emphasis on working with communities and individuals to improve 
their health and social wellbeing” (72). Primary care services include general practice (GP), 
community nursing, occupational therapy, pharmacy, physiotherapy, speech and language therapy 
and social work (72). General practitioners (GPs) are central to the delivery of patient care in the 
Irish primary care context. The estimated number of GPs currently in practice in Ireland is 3,523 (73). 
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Most GPs in Ireland are self-employed, though they provide care which is state funded for GMS 
patients on a contractual basis. Over half of GPs work in group practices of three or more GPs, with 
18% of GPs currently operating as sole practitioners (73).  
Secondary care in Ireland is comprised of 48 public hospitals funded by the state through the Health 
Service Executive (HSE) and 21 private hospitals. The HSE is the national body responsible for the 
delivery of public healthcare in Ireland.  Public hospitals are grouped into three categories based on 
hospital status and level of treatment complexity. Category 1 (the highest level of treatment 
complexity) is comprised of Health Service Executive (HSE) regional hospitals and teaching hospitals, 
Category 2 includes HSE county hospitals and non-teaching hospitals, and Category 3 is made up of 
HSE district hospitals (74).  There are 2951 consultants and 6209 non consultant hospital doctors 
(NCHDs) currently employed within public and private hospitals in Ireland (75). 
The GMS is a public system providing medical cards to patients on the basis of means testing, with 
additional cards being awarded to particular patients with specific medical needs associated with 
high medical expenditure. A full GMS medical card entitles the holder to access their GP and to 
receive public hospital care without incurring any costs. In addition, patients with a full medical card 
receive prescribed medications for the nominal charge of €2.00 for each item that is dispensed, up 
to a maximum of €20 per month per person or family (76). A GMS GP visit card entitles the holder to 
visit a GP without charge, and in 2015, non means tested GP visit cards were given to all patients 70 
years and over and to all children aged less than six years. The GP is paid an annual fee of €43-270 
(dependent on age and gender) per capita by the GMS (77, 78). Ireland is the only EU country in 
which the health system does not cover the cost of accessing a GP for all patients. Patients not 
covered by the GMS pay their GP a fee per consultation (circa €50)(71). 
 All patients in Ireland not covered by the GMS are entitled to subsidised public hospital care. Private 
health insurance covers inpatient and outpatient hospital care. Private hospitals only provide care 
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for patients with private health insurance (74) with  some private care  also being delivered in public 
hospitals alongside public care (71). 
In Ireland, general practice facilitates appropriate access to specialist services and investigations in 
secondary care, operating as a gatekeeper with in the healthcare system for both public and private 
patients.  GPs in Ireland conduct 20 million consultations per annum delivering services in primary 
care ranging from antenatal care to chronic disease management (73, 79). The majority of patients 
attending a GP in Ireland are managed in primary care with a recent Irish study giving a figure of 
approximately one in ten patients for patients referred to secondary care. This proportion of care 
provided in primary and secondary care is in line with findings from other healthcare systems 
internationally (80-82). 
 
1.2.2 Patient population 
 
Data from the 2016 census in Ireland indicates that the population of Ireland is 4.7 million, an 
increase of 12.2% since 2006. The most significant increase has been in the population aged over 65 
years. Each year the population aged over 65 increases by almost 20,000 people, and by almost 
3,000 for those aged 85 years and over (83). Irish figures reflect the global context with the 
population aged 60 years or over worldwide numbering 382 million in 1980, 962 million in 2017 and 
projected to reach nearly 2.1 billion by 2050 (84). A growing aging population results in increased 
prevalence of chronic disease. Furthermore, many of this population have multimorbidity. Thus 
multimorbidity is also increasing worldwide (85-89). Consequently, an increase in healthcare 
utilisation in both primary and secondary care has been noted internationally (89, 90). This is 
likewise reflected by the growing demand for healthcare services among the older adult population 
in Ireland.  Increased frequency of general practice consultations has been described (91).  In 
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addition, figures for hospital admissions in 2015, demonstrated that patients aged 65 years and over 
occupied 53.4% of total hospital inpatient bed days (92). 
 
1.2.3 Political and economic landscape  
 
In 2008, Ireland faced an economic crisis. The Financial Emergency Measures in the Public Interest 
(FEMPI) Act was brought into effect in 2009. Government payments to GPs were reduced as a result 
of this Act. GMS payments to GPs were reduced by 8% in 2009, by a further 8-15% in 2010 and by a 
further 7.5% in 2013 (93). In contrast, during this time, there was a 70% increase in the number of 
patients eligible for a GMS card due to a reduction in their incomes. Many GPs have struggled with 
increasing demand in the context of reduced payment. Emigration of Irish GPs has increased since 
2009 which has resulted in a current manpower crisis in Irish general practice (77, 79). Ireland 
currently has 76 GPs per 100,000 population, compared to Canada or Australia, which have over 100 
per 100,000 population (79). 
 International evidence suggests that increasing numbers of GPs is associated with a consistent 
reduction in  all-cause mortality and improved  self-reported health (94).  Furthermore,  increasing 
spending in primary care can yield up to a six fold return on overall health spending (95, 96). Ireland 
currently spends the fifth highest amount on health in the world, ranking 7th in the Organisation for 
Economic Co-operation and Development (OECD) in terms of spending per capita (97). Recent 
figures  show however  that  just 4.9% of the Irish health budget was allocated to primary care (98). 
High occupancy rates for acute care beds in Ireland are suggestive of excessive numbers of patients 
being treated at a secondary care level (99).  
 The need to move to a primary care centric healthcare system has recently been identified by the 
Irish government and the HSE (100). The need to improve resourcing of primary care has been 
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highlighted with an  additional half a billion euro a year of funding over 10 years recommended  to 
develop  a functioning primary care based healthcare system (77).  
 
1.2.4 The primary secondary care interface 
 
The primary secondary care interface describes the journey of the patient and the communication 
between health care professionals as the patient moves between primary and secondary care (101) 
(102). The integration of health services across primary and secondary care poses a challenge for all 
healthcare systems and the primary secondary care interface has been identified as problematic  for 
healthcare providers and users alike (101, 103). Suboptimal and fragmented patient care has been 
described with the potential for patient harm (104).  Poor co-ordination of care and inadequate 
transfer of patient information have been highlighted as issues (105-107). Achieving successful 
communication between clinicians in primary and secondary care is challenging (108, 109).  
 
Lack of integration between primary and secondary care is a current issue in the Irish healthcare 
system (110). Both  GPs and hospital consultants in Ireland have expressed a willingness to provide 
more seamless patient care but have highlighted the absence of structures to facilitate integrated 
care at a local level (111, 112). Transmission of accurate patient information in a timely manner 
between primary and secondary care has been identified as key to facilitating successful integrated 
care (110).  Efforts have been made to improve transmission of patient information at the primary 
secondary care interface. Guidance has been produced for Irish GPs on referral information being 
sent to secondary care by the Irish College of General Practitioners (ICGP), with standardised paper 
based and electronic referral templates now in existence (113). A document outlining a national 
standard for discharge information was also published in 2013 (114). In practice however, 
transmission of patient information between general practice and hospital remains an issue (110).  
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Up to 20% of an Irish GP’s time during a working day is currently spent on paperwork and 
administrative tasks (115). Contacting hospital staff to clarify issues pertaining to inadequate or 
inaccurate patient information from secondary care  has been identified as a major source of 
frustration for GPs (77), with issues frequently arising in relation to hospital discharge information 
(116, 117). Such information is commonly generated by junior doctors (doctors in their first one to 
two years post qualification) and despite the efforts made to standardise information at this point in 
care, there is considerable variation at a local level. Omissions and inaccuracies are frequently 
reported by GPs (116-118). In addition, timeliness of receipt of discharge information is also an issue 
with information frequently not being received by a patient’s GP for a number of days following 
discharge (116, 118).  
 
Poor availability of up to date and accurate information pertaining to a patient’s medication 
following hospital discharge is of particular concern for GPs (119-121). Pharmacists may only 
dispense a seven day supply of medications to patients who are medical card holders from a 
prescription issued by a hospital doctor (122). Hence, these patients frequently attend their GP 
immediately following discharge to have their medications transcribed onto a GMS prescription. A 
report published in October 2018, whilst acknowledging the role that GPs play in reviewing and 
transcribing prescriptions from hospital doctors in terms of identifying errors pertaining to 
prescribing , also identifies this restriction as a source of inefficiency in general practice (10). 
 
1.2.5  Information Technology (IT) in healthcare 
 
Internationally there has been a move towards the greater use of IT in healthcare and many 
countries have implemented electronic health records (EHR).  In the past 20 years Irish GPs have 
invested in IT and currently more than 90% of GPs in Ireland use electronic patient record systems 
(123). Administrative, clinical, and prescribing details are recorded electronically together with 
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correspondence from other healthcare professionals in primary and secondary care (77). A secure 
clinical email system (Healthmail) was developed in 2014 for all primary healthcare providers in 
Ireland. The majority of users are GPs, with use of the system by pharmacists beginning in 2017 
(124). Systems for electronic referral (e-referral) from general practice to Irish hospitals are also in 
place. 
 IT is less widely used in hospitals in Ireland than in primary care and  infrastructure  is not yet 
sufficiently developed to support a full EHR (110, 125). Use of Healthmail and e-referral varies 
between hospitals (77). In 2004 investment in IT in healthcare and allocation of staff to the health 
information area was recommended as part of the National Health Information Strategy (126). 
However, this investment and allocation of staff did not take place until 2015.  In addition, though an 
individual Health Identifier (IHI) has been identified as key to progression in terms of Electronic 
Health Record (EHR) development and implementation, legislation to facilitate this was not put in 
place until 2014. An IHI has not yet been issued to patients in Ireland (125). Nonetheless, following  
publication of the e-health strategy and the appointment of a Chief Information Officer for health, 
progress has been made recently in the secondary care setting and in November 2016 Cork 
University Maternity Hospital became Ireland’s first  hospital to operate a complete EHR system 
(125).  
Despite the fact that routine electronic communication of patient information between primary and 
secondary care has been identified as crucial to the successful delivery of integrated care in Ireland, 
notwithstanding  recent advances in IT in healthcare, this has yet to be achieved (110).  Current 
practice is the ad hoc transfer of discrete components of patient information between hospital and 
general practice with considerable local variability.  
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1.3 Medication reconciliation 
 
Medication reconciliation, first described in 2003, was named as one of the five elements of the 
WHO High 5’s project addressing patient safety issues in 2006 (127). It  is the term used for the 
process of identifying and correcting medication errors as patients move between different care 
stages and settings (128). The goal is to develop an accurate list of all medications a patient is taking 
that is available at all stages and settings of care, hence effectively communicating changes to 
medications to both the patient and healthcare providers as the patient transitions through the 
healthcare system. It is based on the premise that safe use of medication requires knowledge and 
consideration of all the medications that a patient is taking in order to avoid omissions, duplications, 
dosing errors and potential adverse drug-drug interactions (DDI) with new drugs being prescribed 
(128, 129).  
The WHO outlines seven guiding principles for medication reconciliation as listed in Table 1.1 (128): 
Table 1 1: WHO principles for medication reconciliation 
Guiding principles for medication reconciliation 
1. An up to date and accurate patient medication list is essential to ensure safe prescribing in 
any setting. 
2. A formal structured process for reconciling medications should be in place across all 
interfaces of care. 
3. Medication reconciliation on admission is the foundation for reconciliation throughout the 
episode of care. 
4. Medication reconciliation is integrated into existing processes for medication 
management and patient flow. 
5. The process of medication reconciliation is one of shared accountability with staff aware 
of their roles and responsibilities. 
6. Patients and families are involved in medication reconciliation. 
7. Staff responsible for medication reconciliation are trained to take a medication history 
and reconcile medicines 
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The process of medication reconciliation involves a series of steps outlined in Figure 1.2 (130): 
 
 
Figure 1 2: Process of medication reconciliation 
 
In establishing the best possible medication history (BPMH) it is recommended that a number of 
sources of medication information are used (131). Sources of information include records from the 
hospital, GP and community pharmacy in addition to information held by the patient. The role of the 
pharmacist in establishing an accurate medication history is well established (132, 133) and ideally a 
pharmacist should be involved in establishing the BPMH and the comparison of that list with 
prescribed medication. When a pharmacist is not available it is recommended that the tasks be 
undertaken by a healthcare professional e.g. physician, nurse or pharmacy technician who has been 
appropriately trained (128). The process of medication reconciliation outlined in Figure 1.2 is used in 
Chapter 3 of this thesis. 
Guidance suggests that medication reconciliation should be multidisciplinary and that the patient 
and families/carers should be directly involved in the process resulting in “a conscientious, patient 
centred, inter-professional process that supports optimal medicines management”. It is also 
recommended that the process integrates into usual care (128, 134). Different strategies have been 
Identify all available records of medication information
(Hospital, GP, Community pharmacy)
Obtain medication information from patient
(Actual medications, list , verbal account)
Establish the best possible medication history (BPMH)
Compare the BPMH to the current list of prescribed 
medication
Identify errors and make clincal decisions establishing a 
new medication  list
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reported for medication reconciliation in the literature. The most common interventions described 
are pharmacist led. Interventions employing information technology, education, standardised tools 
and complex multi-faceted approaches have also been described (135-137) . No consensus exists 
regarding the optimal method however (138) . 
A body of evidence exists to support the practice of medication reconciliation.  The process has 
strong face validity; as capturing medication errors of clinical significance has the potential to 
positively impact not only patient morbidity and mortality, but also healthcare costs by preventing 
adverse drug events (128, 139).   Medication reconciliation is currently  widely advocated by 
professional and  accrediting bodies internationally namely; the Joint Commission (USA), the 
Institute for Healthcare Improvement (USA), the National Institute for Health & Clinical Excellence 
(UK), the Canadian Patient Safety Institute, the Institute for Safe Medication Practices (Canada) and 
the Health Information Quality Authority (Ireland) (140-144). 
Difficulties with implementing medication reconciliation across healthcare systems have recently 
been identified however (134, 145, 146). In practice, medication reconciliation interventions may 
not necessarily integrate seamlessly into usual care. Complexity, which affects workflow, and 
resource intensity resulting in opportunity cost, have been highlighted as issues (136, 147). Current 
evidence has failed to demonstrate a significant associated reduction in healthcare costs (136, 147). 
In terms of healthcare utilisation, a Cochrane review published in 2018 concluded that (based on the 
pooled results of five randomized controlled trials) medication reconciliation had little or no impact 
on unplanned prehospitalization with moderate‐certainty evidence (RR 0.72, 95% CI 0.44 to 1.18). It 
was noted that, although the medication reconciliation interventions were similar and all involved 
clinical pharmacist establishing a BPMH, local variability was an issue.  
In practice, medication reconciliation is often implemented only among high-risk patients such as 
complex polypharmacy patients (128).  In the Irish context medication reconciliation is currently 
implemented on an ad hoc basis with implementation frequently restricted to areas such as geriatric 
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medicine. With medication reconciliation representing a potential solution to the growing issue of 
medication error however,  there is an urgent need to look at how cost-effective, universal 
implementation can be achieved  (136).  
 
1.4 Research aim and objectives 
 
Medication error at the primary-secondary care interface is currently a major patient safety issue. 
Within the Irish healthcare system resources are limited. Measures to reduce costs and improve 
process efficiency are required in addition to optimising patient care. Although medication 
reconciliation facilitates the reduction of medication error, complexity and cost are issues and there 
is currently is a dearth of novel interventions to facilitate the process. Examining medication error in 
terms of cost, causes and consequences is essential for the development of an intervention to 
facilitate its reduction. 
 
Aim:  
The aim of this research is to develop an intervention to reduce medication error at the primary 
secondary care interface 
Objectives: 
1. To review existing evidence on the economic impact of medication error 
2. To examine an established intervention (an existing process of medication reconciliation) at 
the primary secondary care interface 
3. To develop a novel intervention to reduce medication error at the primary secondary care 
interface 
4. To evaluate the feasibility of implementation of the intervention  
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1.5 Theoretical framework 
 
The process of developing and introducing an intervention in a healthcare context is complex. Many 
interventions found to be effective in health services research fail to be successfully implemented 
and hence fail to improve patient care (148). Barriers to implementation may occur at multiple 
levels: the patient level, the provider level, the organizational level or the policy level (149). To 
address such issues, the UK Medical Research Council (MRC) recommends a structured 
methodological approach in developing a complex intervention in the healthcare setting.  Systematic 
development is recommended based on best available evidence and appropriate theory (150) . The 
steps recommended in development have been followed in this thesis and are outlined in Figure 
1.3.Following development, the MRC recommends testing of interventions in a phased approach 
beginning with a feasibility study and moving on to exploratory and finally definitive evaluation 
(150).  
 
Figure 1 3: Steps of the development stage of a complex intervention outlined in the MRC 
methodological approach 
 
Step 1 Identifying the existing evidence base: 
Existing evidence has identified medication error as a source of morbidity, mortality and financial 
cost.  The frequent occurrence of medication error at the primary secondary care interface and the 
need for novel interventions to assist with medication reconciliation at this care transition have also 
been described.  
1 
Identifying the existing 
evidence base 
2
Identifying and 
developing theory
3
Modelling process and 
outcomes
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In this thesis the existing evidence was supplemented by new evidence firstly in relation to the 
economic impact associated with medication error (Chapter 2), secondly in relation to deficits in 
knowledge and records of medication among at risk patients at the primary secondary care interface 
(Chapter 3) and thirdly in relation to issues in communication of medication information between 
primary care and secondary care (Chapter 3). 
Step 2 Identifying and developing theory: 
Successful development and implementation of a novel intervention within the healthcare setting 
requires a detailed understanding of the context in which it is being introduced and potential 
barriers to implementation. The development and introduction of intervention at the interface of 
primary and secondary care involves multiple stakeholders (patients, healthcare professionals and 
information technology personnel), and two settings of care. To explore the issues surrounding 
development and implementation, the Consolidated Framework for Implementation Research (CFIR) 
was used and is described in Chapter 4. The CFIR is a meta-theoretical framework. It combines key 
elements from published implementation theories and provides a structure to verify what works, 
where and why across multiple contexts.  It consists of five domains. Each domain consists of factors 
and influences which impact the degree to which an intervention or practice is adopted (151):  
 Intervention characteristics 
 Outer setting 
 Inner setting 
 Characteristics of the individuals involved 
 Process of Implementation 
Step 3 Modelling process and outcomes: 
Modelling a complex intervention before a full scale evaluation can provide important information 
about the design of the intervention and the evaluation.  The MRC guidance states that a series of 
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studies may be required to progressively refine the design before proceeding to full scale evaluation. 
Chapter 4 outlines planning of intervention evaluation and a preliminary assessment of acceptability 
and feasibility.  
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2.1 Abstract  
 
Background 
Medication error is a significant source of morbidity and mortality among patients. Clinical and cost-
effectiveness evidence are required for the implementation of quality of care interventions. 
Reduction of error-related cost is a key potential benefit of interventions addressing medication 
error.   
Aim 
The aim of this review was to describe and quantify the economic burden associated with 
medication error. 
Methods 
The review was registered with PROSPERO 05/08/15 (Registration no: CRD42015024202). A search 
strategy was developed and PubMed, Cochrane, Embase, CINAHL, EconLit, ABI/INFORM and  
Business Source Complete were searched. Studies published 2004-2016 assessing the economic 
impact of medication error were included.  Cost values were expressed in Euro 2015.  A narrative 
synthesis was performed. 
Results 
4572 articles were identified from database searching and 16 were included in the review. 
One study met all applicable quality criteria. 15 studies expressed economic impact in monetary 
terms. Cost per error per study ranged from €2.58 to €111,727.08. Healthcare costs were used to 
measure economic impact in 15 of the included studies with one study measuring litigation costs. 
Four studies included costs incurred in primary care with the remaining 12 measuring hospital costs. 
Five studies looked at general medication error in a general population with 11 studies reporting the 
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economic impact of an individual type of medication error or error within a specific patient 
population. 
Conclusion 
 Considerable variability existed between studies in terms of financial cost, patients, settings and 
errors included. Many were of poor quality. Assessment of economic impact was conducted 
predominantly in the hospital setting with little assessment of primary care impact or impact of errors 
occurring at the primary-secondary care interface.  Limited parameters were used to establish 
economic impact. The economic burden associated with medication error may have been 
underestimated to date. Future work is required to assess economic impact using parameters inclusive 
of health care professional time and costs pertaining to primary care, patients and society.  
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2.2 Introduction 
 
Medication error is a significant source of preventable morbidity and mortality among patients (1). 
The medication use process involves drug prescription, preparation, dispensing and administration. 
Definitions of medication error vary in the literature (152) and errors may occur at any point in the 
medication use process and may involve physicians, pharmacists and nurses in primary, secondary 
and tertiary care settings. Additionally, patients may not take medications as prescribed, a 
phenomenon referred to as medication non-adherence (153).  Medication error may result in 
preventable adverse drug events (pADEs) resulting in patient harm and considerable financial cost 
(1). Not all medication errors result in patient harm but may however be associated with other 
negative consequences such as inefficiency and inappropriate use of resources, contributing to 
economic burden (154).  Medication safety is a key component in quality of patient care and 
developing strategies to reduce medication error is currently an international priority (140) 
Interventions to reduce medication error may target health-care professionals inclusive of 
physicians, pharmacists and nurses and additionally may target patient-non adherence.  Increasingly 
interventions to improve quality of care in the health care sector are required to demonstrate 
effectiveness from both a clinical and cost perspective.  When conducting an economic evaluation of 
a quality improvement intervention the identification, measurement and valuation of both the 
relevant costs and the relevant benefits is required (155). Due to the complex nature of the 
medication error process; interventions to reduce medication error are often multifaceted and 
resource intensive (156, 157). In the case of interventions to reduce medication error, reduction of 
the cost due to error is a key potential benefit.  Hence an accurate estimate of the economic burden 
associated with medication error is necessary to inform the successful development and 
implementation of interventions focussing on its reduction. 
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The aim of this review is to establish the economic impact of errors associated with the prescription, 
preparation, dispensing and administration of medication. Additionally, the review will identify 
methods and parameters used when calculating the cost of medication error and also identify the 
types of medication error that result in economic burden. It will provide evidence for healthcare 
decision makers regarding the costs associated with medication error and will also highlight areas 
requiring further study for practitioners and policymakers. 
 
2.3 Methods 
 
Search strategy 
 
The protocol for the systematic review was registered with PROSPERO 05/08/15 (Registration no: 
CRD42015024202). Searches were conducted of the following databases: PubMed, Cochrane, 
Embase, CINAHL, EconLit, ABI/INFORM and Business Source Complete in June 2015 for publications 
dating back to January 2004. The search was updated in April 2016. The search strategy was 
developed by the primary author in association with a medical librarian. A PubMed Strategy was 
developed and appropriate Medical Subject Headings (MeSH) terminology was utilised. The 
following search terms were employed: (Cost OR Cost analysis OR Econ*) combined with 
(Medication error OR Inappropriate Prescribing OR “Inappropriate Medication” OR Preventable 
adverse drug event* OR Preventable adverse drug reaction* OR Prescribing error* OR Transcription 
Error* OR Medication Discrep* keywords were used for additional databases. (See Appendix 1 for 
the full search strategy).   Search results from multiple databases were transferred to a reference 
manager- End Note. Title review was conducted by the primary author (EW). Studies that clearly did 
not meet eligibility criteria were excluded. Abstract review was performed by the primary author 
and studies that did not meet the inclusion criteria were excluded. Full text review was performed 
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by EW and secondary author (CH). Where disagreement arose between the primary and secondary 
authors regarding study inclusion a third author (LS) was involved and a consensus was reached.  
 
Review criteria and data extraction 
The review was conducted according to the PRISMA guidelines (158). (See Appendix 1) Studies were 
required to meet the criteria specified in Table 2.1. 
Table 2 1: Inclusion and exclusion criteria 
Inclusion criteria                                                                                Exclusion criteria 
Published peer reviewed full text articles                                                                              Non-peer reviewed literature e.g. technical reports,  
                                                                                                                                                       Letters to the editor, newspaper articles    
                                                                                                                                                       Grey literature            
Studies published in the English language 
Studies focussing on errors in the prescribing, transcribing, dispensing                         Studies focussing on the prescribing of potentially  
or administration of medication                                                                                             inappropriate medications, non-compliance or non-   
                                                                                                                                                      adherence to medication. 
                                                                                                                                                      Studies focussing on non-preventable adverse 
                                                                                                                                                      drug reactions 
 
                                                                                                                                                      Studies focussing on errors in drug manufacturing 
Studies focussing on the economic burden associated with medication                        Economic evaluations of interventions to reduce  
error                                                                                                                                              error 
                                                                                                                                                      Studies evaluating non-medication related medical  
                                                                                                                                                       error 
                                                                                                                                                      Studies comparing costs of adverse drug reactions 
                                                                                                                                                      of two or more medications    
                                                                                                                                                      
Medication error was defined as “an unintended failure in the drug treatment process that leads to, 
or has the potential to lead to, harm to the patient” as per the European Medicines Agency (EMA) 
Good Practice Guide on recording, coding, reporting and assessment of medication errors (62).   
Failure in the drug treatment process was defined as human or process mediated failures rather 
than lack of efficacy of the drug and included errors of omission. Four categories of medication 
errors were included in the review: 
1. Medication errors with harm 
2. Medication errors without harm 
3. Intercepted medication errors 
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4. Potential medication errors 
 
 The definition does not include adverse drug events and adverse drug reactions that are non-
preventable. For studies assessing the economic impact of adverse drug reactions or events, each 
study was required to specify in the methods section that adverse drug events or reactions were 
preventable, avoidable or directly due to medication error. If not specified, the study was excluded 
from the review.  Additionally, the prescribing of potentially inappropriate medications and non-
compliance/non-adherence to medication were not included in the definition of medication error 
used in this review. Inappropriate prescribing refers to the use of a drug where the risk of an adverse 
drug event outweighs the clinical benefit, particularly if a safer or more effective alternative therapy 
is available (37). Potentially inappropriate prescribing refers to such inappropriate prescribing as 
identified by standardised tools such as Beer’s criteria and STOPP/START (37). Not all potentially 
inappropriate medications detected in this manner necessarily represent medication error however.  
The possibility exists of an intentional and informed decision on the part of the prescriber rather 
than the occurrence of true medication error. 
 
The references of eligible studies and previously published systematic reviews were hand searched 
to identify any additional studies pertaining to the economic impact of medication error not 
captured by database searching.  Studies which met the inclusion criteria were reviewed and data 
extracted by the primary and secondary authors (EW and CH) using a data collection form. (See 
Appendix 1) 
Information collected included details of authors, type of medication error, study setting, study 
population, study sample size, economic method, outcome measures and results.  
Quality assessment: 
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Due to the lack of risk of bias assessment tools or established methodological guidance on how to 
conduct a critical appraisal of the economic burden of medication error, assessment of study quality 
was challenging.  Due to variability in terms of study design of the included studies standardised 
tools assessing quality from an epidemiological perspective could not be applied universally to the 
studies (159). Additionally, other checklists for critical appraisal of economic studies pertained 
specifically to economic evaluations and could not be applied (160, 161). As cost-of-illness studies 
aim to assess the economic burden of particular health conditions on the general population a tool 
used for critical appraisal of cost of illness studies was sought. A number of tools used in previous 
studies for quality assessment were potentially applicable to the included studies (162-165).  The  six 
parameters  pertaining to cost-of illness as described by Cooper et al incorporated the key 
components of the quality assessment tools reviewed (165). Quality assessment was conducted 
using the parameters described by Cooper et al with the addition of a parameter pertaining 
specifically to medication error. No study was excluded based on quality assessment. The 
parameters used are outlined below:  
The approach used for quality assessment was applicable to all of the included studies but only 
assessed quality from economic and error reporting perspectives.   
1. Viewpoint/perspective (e.g. patient/health service) of the analysis clearly stated and 
justified. 
2. Study population clearly stated. 
3. All relevant medical and/or non-medical costs included and their sources clearly stated. 
4. All costs adjusted for differential timing, where appropriate: discounting applied to costs if a 
study was conducted over > 1 year. 
5. Incremental/attributable costs calculated:  calculation of difference in costs incurred by the 
study population and a non-exposed population.  
6. Sensitivity analysis performed to address uncertainties or methodological controversy. 
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An additional seventh parameter was added to assess study quality based on the EMA guidance 
on the appropriate recording and reporting of medication errors (62):  
7. Clear statement if reported costs pertained to an actual or potential error and if the error was 
associated with harm 
Data Synthesis 
 A narrative synthesis was performed using the approach described by Popay et al (166): 
1. Results were tabulated and a preliminary synthesis performed. 
2. Data were transformed and a common rubric established so as to express the results in a 
common numerical value. Costs in all studies were expressed in Euro 2015 values and a cost 
value per medication error was calculated where data were available. 
3. Relationships within and between studies were explored. 
4. Robustness of the synthesis was assessed. 
 
Subgroup analysis was stated a priori and was conducted by age (> or < 65 years) and type of 
medication error.  
 
In order to adjust for the inflation rate over time cost in each of the studies was inflated to 2015 
values using the consumer price index (CPI) for medical and non-medical resources for each 
individual country (167).  Each value was then converted to Euro using the exchange rate from 
November 2015. Where year of currency was absent from the study, the year of publication was 
used (Appendix 1). 
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2.4 Results:  
 
Following elimination of duplicates, the search strategy yielded 4572 titles for review. Reasons for 
exclusion are outlined in Fig 2.1. Disagreement arose regarding inclusion of one study between the 
primary and secondary authors (EW and CH). The definition of medication error used in this study 
was “harm resulting from not following the professional standard or poor organisation of care” 
(168). The meaning of the term “professional standard” was unclear.  Prescribing appropriateness 
indicators could be regarded as a professional standard raising the possibility of potentially 
inappropriate prescribing rather than true medication error as per the inclusion criteria.  The opinion 
of a third author (LS) was sought and a consensus was reached to include the study.  
A summary of the 16 studies which met inclusion criteria is listed in Table 2.2. The studies were 
conducted in the USA (n=7), Europe (n=5) Asia (n=3) and South America (n=1). 
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After searching databases and 
removal of duplicates 4572 titles 
were reviewed 
At title review stage 4080 were excluded. 
Reasons for exclusion: 
 192 duplicate papers not recognised 
by Endnote 
 1010 interventions to reduce 
medication error 
 47 other forms of medical error 
 380 no economic aspect 
 348 other economic evaluation 
 1874 unrelated to medication error 
 228 guidance policy/education 
 
At the abstract review stage 372 articles were 
excluded. Reasons for exclusion: 
 17 interventions to reduce 
medication error 
 149 no economic component 
 11 economic focus unrelated to 
medication error 
 92 did not comply with definition of 
medication error (e.g. included non-
adherence) 
 99 commentary or editorial 
 4 research in progress 
 
105 papers were excluded following review of 
full text. Reasons for exclusion: 
 19 conference abstracts 
 12 reviews or commentaries or case 
reports 
 6 no cost data 
 68 did not comply with definition of 
medication error 
 
491 articles underwent abstract 
review 
119 papers underwent full text 
review 
 
2 papers were identified from 
reference searching-a total of 121 
papers underwent full text review 
16 papers were eligible for 
inclusion in the systematic review 
Figure 2 1: Reasons for exclusions of studies 
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First author 
Year 
 
 
 
 
 
 
 
Title 
 
 
 
 
 
 
 
Study design 
 
Methods used to 
identify  error 
 
 
 
 
 
 
 
Study 
population 
 
Study setting 
 
 
 
 
 
 
 
Sample 
size 
patients 
 
 
 
 
 
 
 
Sample 
size  
errors 
 
 
 
 
 
 
 
Type of 
medication 
error (EMA 
Classification*) 
 
 
 
 
 
 
 
Economic 
method 
 
 
 
 
 
 
 
 
Outcome 
measure 
 
 
 
 
 
 
 
Results 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Choi (169) 
2016 
 
 
 
 
 
 
Samp (170)    
2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incidence and 
treatment costs 
attributable to 
medication errors in 
hospitalized 
patients 
 
 
Economic 
evaluation of the 
impact of 
medication errors 
reported by US 
clinical pharmacists 
 
 
 
 
 
 
 
 
 
 
 
 
Case control: 
Retrospective review 
of voluntary error 
reports completed by 
physicians, 
pharmacists and 
nurses 
 
Cross sectional: 
Retrospective review 
of errors observed by 
clinical pharmacists in 
practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital in 
patients 
(secondary 
/tertiary care), 
USA 
 
 
 
Patients in 
primary/ 
secondary/ 
tertiary care, 
USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
57,554 
 
 
 
 
 
 
 
Not 
stated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
470 
 
 
 
 
 
 
 
 
779 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Error of ordering, 
transcription, 
dispensing and 
administration. 
Errors with harm 
and without harm 
 
 
pADE **(Any 
preventable event 
that may cause or 
lead to 
inappropriate 
medication use or 
patient harm) 
Errors with harm 
Errors without 
harm 
 
 
 
 
 
 
 
 
Measuring of 
direct costs via 
recycled 
prediction and 
Blinder-Oaxaca 
methods  
 
 
Measuring of 
direct costs, 
Economic 
modelling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional hospital 
treatment costs 
incurred by patients 
experiencing a 
medication error 
 
 
 
Costs due to error: 
-monitoring (costs 
of monitoring tests) 
-medication 
regimen change 
(pharmacists 
dispensing fee) 
-permanent harm to 
patient (equated to 
harm resulting from 
stroke) 
combined with the 
probability of the 
outcome occurring 
 
 
 
 
470 errors costed (with and without 
harm): 
Recycled prediction method: 
€8278.94 
Blinder-Oaxaca decomposition 
method: 
€7851.87  
 
Cost per error (with and without 
harm):  
1 €85.82 (base case) 
2€ 86.58 USD 
 (Monte Carlo simulation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies reporting the economic impact of general medication error 
Table 2 2: Studies included in the systematic review 
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Hughes (171) 
2012 
 
 
 
 
 
 
 
 
 
 
Hoonhout 
(168) 
2010 
 
 
 
 
 
 
 
 
 
Pinilla (172)      
2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cost of adverse 
drug events in 
community 
hospitals 
 
 
 
 
 
 
 
 
Nature, occurrence 
and consequences 
of medication-
related adverse 
events during 
hospitalisation. A 
retrospective chart 
review in the 
Netherlands 
 
 
 
Case control 
analysis of the 
financial cost of 
medication errors in 
hospitalised 
patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparative study 
(Case V total study 
population 
comparison): 
Retrospective review 
of patient records to 
identify preventable 
adverse drug events 
 
 
 
 
Cross sectional: 
Retrospective review 
of patient records by a 
nurse and 2 physician 
reviewers to identify 
preventable adverse 
drug events 
 
 
 
 
 
Case control: 
Retrospective review 
of voluntary error 
reports completed by 
physicians, nurses and 
pharmacists 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital             
inpatients 
(secondary/ 
tertiary care,) 
The 
Netherlands 
 
 
 
 
 
 
Adult inpatients 
in community 
hospitals 
(secondary 
care), USA 
 
 
 
 
 
 
 
Adult inpatients 
in private 
hospital 
(tertiary care), 
Spain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,100 
 
 
 
 
 
 
 
 
 
 
 
7,889 
 
 
 
 
 
 
 
 
 
 
 
172 (86 
per arm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 
 
 
 
 
 
 
 
 
 
86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pADE** (an error 
in the process of 
ordering, 
delivering or 
administering a 
drug resulting in 
patient harm) 
Errors with harm 
 
 
 
 
pADE** (harm 
caused by 
medication due to 
not following the 
professional 
standard or poor 
organisation of 
care) 
Errors with harm 
 
 
 
Errors of 
validation, 
dispensing, 
administration, 
inattention, 
illegibility, 
labelling, 
packaging, lack of 
recording, 
misinterpretation 
Errors with harm 
Errors without 
harm 
 
 
 
 
 
 
 
 
 
Measuring of 
direct costs, 
opportunity and 
capital costs 
 
 
 
 
 
 
 
 
Measuring of 
direct costs 
(potential costs) 
 
 
 
 
 
 
 
 
 
Measuring of 
direct costs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional costs 
incurred by cases: 
1 Hospitalisation 
cost (Operating 
cost, capital cost) 
2 Length of hospital 
stay 
Unadjusted 
Adjusted for age, 
sex, illness severity, 
individual hospital  
 
Potential clinical 
costs as decided by 
an expert panel: 
1 Excess length of 
stay 
2 Excess 
hospitalization costs 
 
 
 
 
 
Only errors reaching 
the patient were 
costed 
Additional costs 
incurred by 
patients: 
1 Hospital costs 
(cost of stay, drugs, 
radiology. 
Healthcare 
material) 
2 Length of stay 
 
 
 
 
 
 
 
 
 
 
Cost per error (with harm): 
1 Increase in average hospitalisation 
cost €6432.16/€4659.76 
(mean/median) 
2 Increase in average length of stay 
unadjusted 
4.64/4.0 days (mean/median) 
adjusted 3.37/2.36 days 
(mean/median 
 
 
 
Cost per error (with harm):  
1 Excess length of stay 6.9 days (95% 
CI 2.2, 7.8) 
2 Excess hospitalisation costs 
€3456.38 (95% CI €1172.,€6105.14) 
 
 
 
 
 
 
 
63 errors costed (with and without 
harm): 
1 €2184.93/€1510.15(mean/median) 
greater hospital costs 
2 303days of additional 
hospitalisation 
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Zaidi (173) 
2015 
 
 
 
 
 
 
 
 
Zahari (174)  
2014 
 
 
 
 
 
 
 
Gharekhani 
(175) 
2014 
 
 
 
 
 
 
 
Al-lela (176) 
2012 
 
 
 
 
 
 
Quantifying and 
reducing inhaler 
prescription errors 
in secondary care 
 
 
 
 
 
 
Duplication of 
oxycodone 
prescriptions at 
pharmacy 
department, 
Hospital University 
Sains Malaysia 
(HUSM) 
 
Frequency, types 
and direct related 
costs of medication 
errors in an 
academic 
nephrology ward in 
Iran 
 
 
Estimation of 
immunization 
providers’ activities 
cost, medication 
cost and 
immunization dose 
errors 
 
 
 
 
 
Cross sectional:  
Review of incorrect 
prescriptions by 
pharmacists 
 
 
 
 
 
 
Cross sectional: 
Retrospective, 
prescription review 
 
 
 
 
 
 
Cross sectional: 
Prospective, detection 
of medication errors 
by clinical pharmacists 
on a nephrology ward 
 
 
 
 
Cross sectional: 
Retrospective review 
of immunisation 
records 
 
 
 
 
 
Hospital 
inpatients 
prescribed an 
inhaler 
(secondary/ 
tertiary care), 
UK 
 
 
 
Hospital 
inpatients 
Prescribed 
oxycodone 14-
90 years 
(secondary/ 
tertiary care),  
Malaysia 
 
Adult inpatients 
prescribed 1 or 
more 
medications 
in a hospital 
nephrology 
ward (tertiary 
care), Iran 
 
Children 0-
18months in 
Public Health 
Clinic (primary 
care), Iraq 
 
 
 
 
 
 
Not 
stated 
 
 
 
 
 
 
 
 
212   
 
 
 
 
 
 
 
 
350 
 
 
 
 
 
 
 
 
528  
 
 
 
 
 
 
 
 
 
61 
 
 
 
 
 
 
 
 
 
103 
 
 
 
 
 
 
 
 
1372 
 
 
 
 
 
 
 
 
483 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prescription error 
(incorrect device, 
strength or drug) 
Intercepted 
medication errors 
 
 
 
 
 
Prescription error 
(duplication) 
EMA 
Classification 
unknown 
 
 
 
 
Prescription 
errors, 
transcription 
errors, drug 
administration 
errors 
Intercepted 
medication errors 
 
Unnecessary 
(early) and invalid 
(extra) 
immunisation 
dose 
EMA classification 
unknown 
 
 
 
 
 
 
Measuring of 
direct cost 
 
 
 
 
 
 
 
 
Measuring of 
direct cost 
 
 
 
 
 
 
 
Measuring of 
direct costs 
 
 
 
 
 
 
 
Measuring of 
direct costs 
 
 
 
 
 
 
Cost of erroneous 
medication 
 
 
 
 
 
 
 
 
Cost of medication 
 
 
 
 
 
 
 
 
Medication cost 
 
 
 
 
 
 
 
 
1 Cost of vaccine 
2 Cost of service 
(time and average 
salary of 
administrator, 
physician and 
nurse) 
 
 
 
 
 
 
 
 
 
 
Cost per error (intercepted error): 
€67.93 (mean) 
 
 
 
 
 
 
 
 
Total cost (EMA Classification 
unknown) 
€3308.80 
 
 
 
 
 
 
1372 errors costed (intercepted):  
€7683.20 
 
 
 
 
 
 
 
483 errors costed (EMA classification 
unknown): 
288 Early vaccine doses:  
Vaccine cost €244.51                                                       
Service Cost €497.14                 
195 Extra doses:                
Vaccine Cost € 176.52                                                        
Service Cost €325.30 
Total cost:  €1243.47 
Studies reporting the economic impact of an individual type of medication error or error within a specific population 
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Lahue (177) 
2012 
 
 
 
 
 
 
 
 
 
Ranchon 
(178) 
2011 
 
 
 
 
 
 
 
 
 
 
Hellinger 
(179) 
2010 
 
 
 
 
 
 
 
 
National burden of 
preventable adverse 
drug events 
associated with 
inpatient injectable 
mediations: 
healthcare and 
professional liability 
costs 
 
 
Chemotherapeutic 
errors in 
hospitalised cancer 
patients: 
attributable damage 
and extra costs 
 
 
 
 
 
 
 
The cost and 
incidence of 
prescribing errors 
among privately 
insured HIV patients 
 
 
 
 
 
 
Case control: 
Retrospective review 
of medication error 
reporting system 
database for 
preventable adverse 
drug reactions with 
classification by 2 
independent 
physicians 
 
Cross sectional: 
Prospective, 
observation of routine 
practice with errors 
being detected by 
pharmacists, 
pharmacy technicians, 
physicians, nurses,  
 
 
 
 
 
Comparative (exposed 
V unexposed): 
Retrospective review 
of health insurance 
database to detect 
prescription of anti-
retroviral drugs and 
interacting drugs 
 
 
 
Hospital 
inpatients in 
receipt of an 
injectable 
medication 
(secondary/ 
tertiary care), 
USA 
 
 
 
Patients 
receiving anti-
neoplastic 
agents in  
inpatient and 
day care units 
(secondary/ 
tertiary care), 
France 
 
 
 
 
Patients with 
HIV with private 
health 
insurance in 
primary/ 
secondary/terti
ary care, USA 
 
 
 
 
37,513 
 
 
 
 
 
 
 
 
 
 
341 
 
 
 
 
 
 
 
 
 
 
 
 
12,226 
 
 
 
 
 
 
 
 
 
 
303 
 
 
 
 
 
 
 
 
 
 
449 
 
 
 
 
 
 
 
 
 
 
 
 
644 
 
 
 
 
 
 
 
 
 
 
pADE** (an injury 
occurring as a 
result of an error 
in the medication 
use process) 
Errors with harm 
 
 
 
 
 
Errors of 
prescription, 
preparation, 
administration 
Intercepted 
medication errors 
 
 
 
 
 
 
 
Drug-drug 
interaction 
Unknown EMA 
classification 
 
 
 
 
 
 
 
Measuring of 
direct costs, 
modelling 
 
 
 
 
 
 
 
 
Measuring of 
direct costs 
(potential costs) 
 
 
 
 
 
 
 
 
 
 
Measuring of 
direct costs  
 
 
 
 
 
 
 
 
 
Additional costs 
incurred by cases: 
-Inpatient services 
-Post discharge 
physician services 
 
combined with the 
probability of a 
pADE occurring 
 
 
Potential clinical 
costs as decided by 
an expert panel 
1 Cost of new 
potential 
hospitalisation 
2 Cost of potential 
prolongation of 
hospitalisation 
3 Cost of 
medication 
4 Length of stay 
 
Annual healthcare 
utilisation cost 
incurred by those 
exposed to error: 
-Inpatient: cost of 
stay, laboratory, 
physician fee 
-Outpatient: all 
services physician’s 
fees in outpatient & 
emergency dept  
Cost of errors (with harm): 
1 Cost of pADEs per hospital 
admission: €2879.03 (95% CI 
€2507.54, €3343.39) 
2 Annual additional cost of pADEs in 
USA: 
 €3.65 billion (95% CI €2.51, €4.73) 
3 Average annual inpatient cost of 
pADEs per hospital: €576,420 
 
 
449 errors costed (intercepted 
errors): 
1 Cost new potential hospitalisation  
€9678.87  
2 Cost potential prolongation of 
hospitalisation  
€65961.38 
3. Medication cost 
€25842.29 
Total 1-3: 101482.54 
4 216 additional hospital days 
 
 
Additional annual cost (EMA 
classification unknown): 
€4, 337.52 
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Cranshaw 
(180) 
2009 
 
 
 
 
Litigation related to 
drug errors in 
anaesthesia: an 
analysis of claims 
against the NHS in 
England 
 
 
 
 
Cross sectional: 
Retrospective 
review of National 
Health Service (NHS) 
litigation authority 
database of clinical 
claims made against 
the NHS from patients 
alleging harm from 
drug errors in 
anaesthesia 
 
 
 
 
 
Patients 
alleging harm 
from drug 
errors in 
anaesthesia in 
hospital 
(secondary/ 
tertiary care), 
UK 
 
 
 
 
 
1067 
 
 
 
 
62 
 
 
 
 
Drug 
administration 
error (wrong 
drug, dose, order, 
route or drug 
omission) 
Errors with harm 
 
 
 
 
Measuring of 
direct costs 
 
 
 
 
Cost of clinical 
claims made against 
the NHS by patients 
 
 
 
 
62 errors costed (with harm): 
 €6,927078.96 
 
 
         
    
 
 
 
 
      
          
          
Meissner 
(181) 
2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The rate and costs 
attributable to 
intravenous patient 
controlled analgesia 
(IV PCA) errors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cross sectional: 
Retrospective review 
of database of 
medication errors 
reported on a 
voluntary basis by 
nurses and 
pharmacists 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital 
inpatients in 
receipt of IV 
PCA 
 (secondary/ 
tertiary care), 
USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not 
stated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2356 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Errors of 
communication, 
name confusion, 
storage, human 
factors, systems, 
ignored 
contraindications, 
equipment 
Errors with harm 
Errors without 
harm 
 
 
 
 
 
 
 
 
 
 
Measuring of 
direct and 
opportunity costs 
(potential costs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potential clinical 
costs due to error as 
decided by an 
expert panel: 
Direct costs: 
additional drug 
therapy, lab tests, 
radiology, hospital 
length of stay, 
medical supplies, 
labour-nurse, 
pharmacist, 
physician 
Opportunity costs: 
missed revenue 
from the hospital 
that could have 
been generated 
should the error not 
have occurred have 
occurred 
Cost per error (with and without 
harm): 
-Overall: 
€827.99 (mean) 
-Communication 
€1312.58 (mean) 
-Name confusion 
€101.31 (mean) 
-Storage: 
€262.29 (mean) 
-Human factor 
€803.76 (mean) 
-Systems error: 
€1004.13(mean) 
-Contraindicated: 
€657.41 (mean) 
-Equipment related 
€1338.47(mean) 
-Default: €451.41 (mean) 
63 errors (with and without harm) 
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Moura (182) 
2009 
 
 
 
 
 
 
 
 
 
Field (183) 
2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug-drug 
interactions 
associated with 
length of stay and 
cost of 
hospitalisation 
 
 
 
 
 
The costs associated 
with adverse drug 
events among older 
adults in the 
ambulatory setting 
 
 
 
 
 
 
 
 
 
 
Comparative study 
(exposed V 
unexposed): 
Retrospective review 
of hospital pharmacy 
prescription records 
for drug interactions 
 
 
 
 
Case control:  
Retrospective review 
of ambulatory medical 
records for 
preventable adverse 
drug events by trained 
clinical pharmacists 
and classification by a 
pharmacist and 
nehprologist 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital 
inpatients > 18 
yrs, length of 
stay>24hours 
 (secondary 
/tertiary care), 
Brazil 
 
 
 
 
Elderly patients 
(65 years and 
over) enrolled 
in Medicare in 
ambulatory 
care: 
multispecialty 
group practice 
(primary care), 
USA 
 
 
 
 
 
 
 
 
 
 
 
 
589 
 
 
 
 
 
 
 
 
 
 
2500 
(1225 per 
arm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 
 
 
 
 
 
 
 
 
 
 
323 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug-drug 
interaction 
EMA 
Classification 
unknown 
 
 
 
 
 
 
pADE** (Injury 
resulting from a 
drug error) 
Errors with harm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measuring of 
direct costs 
 
 
 
 
 
 
 
 
 
Measuring of 
direct costs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Additional length 
of hospital stay 
patients exposed to 
drug-drug 
interaction  
2 Association of 
exposure to drug-
drug interaction 
with high cost of 
hospitalisation 
 
Additional health 
service utilization 
cost incurred by the 
case group: 
-Inpatient stay 
-Emergency 
Department visit 
-Outpatient care  
-Pharmacy (drug 
cost) 
 
 
1 €2184.93/€1510.15 (mean/median) 
greater hospital costs 
2 303 days of additional 
hospitalisation 
 
Economic impact (EMA classification 
unknown): 
1 Increased mean length of stay of 7 
days 
2 Positive association with high cost 
of hospitalisation (OR 3.1, 95% CI 
2.19-4.42) 
 
 
 
 
Cost per error (with harm):  
€1867.08 (95%CI €244.51, €4779.98) 
 
 
 
 
 
 
 
 
 
*European Medicine’s Agency (EMA) Classification:  
1. Medication errors with harm 
2. Medication errors without harm 
3. Intercepted medication errors 
4. Potential medication errors 
**pADE: Preventable Adverse Drug Event 
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Quality Assessment 
Table 3 outlines the parameters used to assess study quality. The viewpoint adopted was explicitly 
stated in only four of the studies (170, 172, 177, 181) but could be implied by the cost data used in 
all cases. The study population was provided by all studies, as was a clear description of the costs 
used in the analysis. Discounting was applicable to four of the included studies but was not 
conducted in any of the four studies. All other studies estimated costs over a one-year period or less. 
Less than half (n=7) of the studies measured incremental costs with a sensitivity analysis being 
conducted in only two of the included studies. Nine of the included studies reported medication 
errors as per the EMA guidance (62).  Only one of the included studies fulfilled all applicable quality 
criteria (177). 
Table 2 3: Assessment of study quality 
Study Viewpoint Population Relevant 
costs 
Discounting Incremental 
costs 
Sensitivity 
analysis 
Costs reported 
as per EMA* 
guide 
Choi (169) [+] + [+] 0 + 0 [+] 
Samp (170) + + [+] N/A 0 + + 
Hughes 
(171) 
[+] + [+] 0 [+] 0 + 
Hoonhout 
(168) 
[+] + [+] N/A 0 + + 
Pinilla (172) + + [+] N/A + 0 + 
Zaidi (173) [+] + 0 N/A 0 0 [+] 
Zahari (174) [+] + 0 N/A 0 0 0 
Gharekhani 
(175) 
[+] + [+] 0 0 0 0 
Al-lela (176) [+] + [+] N/A 0 0 0 
Lahue (177) + + [+] N/A + + + 
Ranchon 
(178) 
[+] + [+] N/A 0 0 + 
Hellinger 
(179) 
[+] + [+] N/A [+] 0 0 
Cranshaw 
(180) 
[+] + [+] N/A 0 0 + 
Meissner 
(181) 
+ + + 0 0 0 + 
Moura (182) [+] + [+] N/A + 0 0 
Field (183) [+] + [+] N/A + 0 + 
Notation based on Rothfuss et al (184): +, present; [+], partly fulfilled; 0, absent. N/A, non-applicable 
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*EMA: European Medicines Agency 
 
Study design and population: 
Nine studies were cross-sectional in design (168, 170, 173-176, 178, 180, 181) four of case-control 
design (169, 172, 177, 183)and three comparative studies of modified case-control design (171, 179, 
182)  
Studies were conducted primarily among hospital inpatients (n=12) (168, 169, 171-175, 177, 178, 
180-182) with four studies including patients in primary care (170, 176, 179, 183) ; two of which 
assessed economic impact exclusively among primary care patients (176, 183). 
The majority of studies (n=15) examined economic impact of error in an adult study population (168-
175, 177-183). Of these 15 studies, two examined economic impact in elderly patients (>65 years) 
(168, 183). Field et al assessed economic impact of medication error solely among elderly patients 
(183) whereas Hoonhout et al completed a separate assessment of economic impact of medication 
error in patients <65 years and >65 years respectively (168). A further eight of the included studies 
examined economic impact within specific patient groups namely: patients experiencing drug errors 
during anaesthesia (180),  hospital inpatients on a nephrology ward (175), patients with HIV (179), 
hospital inpatients in receipt of an injectable medication (177), hospital inpatients in receipt of 
intravenous patient controlled analgesia (181), hospital inpatients in receipt of anti-neoplastic 
agents (178), patients prescribed oxycodone (174) and hospital inpatient prescribed inhaled 
medication (173). A single study described economic impact in a paediatric population (children 0-18 
months)(176).    
Methods used to establish economic impact: 
Of the included studies 12 measured actual costs pertaining to medication errors to which the study 
population was exposed (169, 171-177, 179, 180, 182, 183).   Three studies measured potential costs 
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due to medication error as decided by an expert panel (168, 178, 181). Three studies used economic 
modelling (169, 170, 177). The first of these calculated costs using economic methods inclusive of 
variables such as age, sex and co-morbidity (169). The second combined the costs of errors detected 
among the study population with the probability of the error occurring (177) and the third combined 
the cost of errors detected with the probability of the outcome measure occurring (170). 
Parameters used to establish economic impact: 
Healthcare costs: 
Of the included studies, fifteen calculated healthcare costs associated with medication error (168-
179, 181-183). Healthcare costs were comprised of costs associated with hospitalisation, medication, 
outpatient care and primary care. The parameter used most frequently to establish economic impact 
of medication error in the included studies was cost of hospitalisation (n=11 )(168-172, 177-179, 
181-183).   
1. Hospitalisation costs:  
A total of 11 studies measured hospitalisation costs, all demonstrating increased economic burden 
associated with medication error (168-172, 177-179, 181-183). One of the studies using 
hospitalisation costs expressed economic impact in terms of increased mean length of stay and a 
positive association with a high cost of hospitalisation (182).  In the 10 other studies that expressed 
economic impact in monetary terms; five used health insurance databases (170, 177-179, 183) to 
calculate hospitalisation costs, three used hospital account information (169, 171, 172), one used a 
combination of information from hospital accounts and health insurance databases (168) and one 
used a combination of fee schedules and published literature (181). The definition of hospitalisation 
costs varied between all 11 studies.   
Six of the included studies used hospitalisation costs as an isolated measure of economic impact 
(168, 169, 171, 172, 181, 182). Moura et al assessed economic impact among hospital inpatients in 
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Brazil exposed to prescribing error.  Economic impact was not expressed as a monetary figure but 
rather by mean length of hospital stay and association with cost of hospitalisation in exposed 
patients (182).  In an American study Choi et al described excess hospital treatment costs for those 
experiencing a medication error. No breakdown of costs was given and hospital database 
information was used to calculate costs (169) . In a study conducted among hospital inpatients in the 
Netherlands Hoonhout et al described excess hospitalisation costs among those experiencing a 
pADE. Costs pertaining to medical and nursing staff, drugs, equipment, inpatient stay and medical 
procedures were described. A combination of hospital account information and health insurance 
(Dutch Healthcare authority) information were used in this study (168). In a Spanish study Pinilla et 
al calculated additional hospitalisation costs incurred by patients experiencing medication error. 
Costs were inclusive of inpatient stay, drugs, scans and healthcare material and hospital account 
information was used to calculate costs (172). 
 Two of the studies using hospitalisation costs as an isolated measure of economic impact used more 
in-depth costing (171, 181).  Hughes et al calculated additional hospitalisation costs incurred by 
patients experiencing a pADE. The study was conducted among hospital inpatients in the USA and 
additional hospital operational and capital costs were calculated using hospital account information. 
Hospital operating cost was defined as “the fixed and variable costs for operating a hospital for 
example, labour and maintenance” and capital costs defined as “the infrastructural cost of buildings 
and equipment” (171). Meissner et al calculated hospitalisation costs among hospital inpatients 
experiencing medication error relating to intravenous patient controlled analgesia (IV PCA). Costs 
were inclusive of medication, laboratory tests, radiological imaging, inpatient stay, medical supplies, 
medical pharmacy and nursing staff. Additionally, Meissner et al included missed hospital revenue or 
opportunity cost defined as “income that could have been generated should the error not have 
occurred” when calculating hospitalisation costs. Costs were calculated using fee schedules and 
published literature (181). 
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 A further five studies used hospitalisation costs in combination with other measures. Field et al 
assessed the economic impact of pADEs among elderly ambulatory patients in the USA.  
Hospitalisation costs in this study were inclusive of inpatient stay and emergency department visits. 
Additionally, medication costs and outpatient costs inclusive of physician fee, diagnostic tests, 
laboratory tests, home health visits, medical equipment and ambulance fee were calculated using a 
health insurance (Medicare) database (183). Hellinger et al assessed the economic impact of 
prescribing error among patients with HIV in the USA. Hospitalisation costs inclusive of inpatient 
stay, laboratory and physician fee were calculated as were additional outpatient costs inclusive of all 
services and physician fees in outpatient and emergency departments using health insurance 
(Marketscan) database information (179).  Lahue et al described economic impact associated with 
pADEs among hospital inpatients in the USA in receipt of an injectable medication.  Hospitalisation 
costs defined as inpatient services were calculated with additional costing of post discharge 
physician services using health insurance (Medicare) cost (177). Ranchon et al calculated 
hospitalisation costs inclusive of inpatient stay in addition to medication costs in hospital inpatients 
in France receiving anti-neoplastic agents who were exposed to medication error. Cost information 
was obtained from the French health insurance system (178). Samp et al assessed economic impact 
in patients experiencing a pADE by using 3 parameters: (1) hospitalisation costs represented by 
inpatient monitoring costs, (2) cost of changes in medication defined as a pharmacists dispensing fee 
and (3) costs of permanent harm to a patient defined as the cost of a stroke.   Cost information was 
obtained from health insurance database (Medicare) information and from the literature (170).  
2. Medication costs:  
Cost of medication was used as a measure of economic impact in eight of the included studies. All 
8studies demonstrated an increase in medication costs due to medication error. Methods to 
determine the cost of medication varied between studies and in three of the studies it was not 
explicitly stated how cost of medication error was calculated. 
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Three studies used medication cost as the sole measure of economic impact (173-175). Gharekhani 
et al calculated the economic impact of medication error among patients on a nephrology ward in 
Iran by calculating the cost paid by the patient or the patient’s insurance agency for erroneous 
medications and the equipment required for medication administration such as syringes or infusion 
sets (175). Zahari et al calculated the cost of medication error due to prescription duplication and 
defined cost of medication   broadly as “current drug price”(174). Zaidi et al calculated the cost of an 
incorrectly prescribed inhaler using the hospital drug formulary (173). 
Medication cost was used to measure economic impact in combination with other parameters in 6 
other studies (168, 172, 176, 178, 181, 183). Al-lela et al reported the cost of erroneous childhood 
vaccines and used medication cost in combination with immunisation service cost. Medication cost 
was calculated as vaccine cost obtained from the Department of Health (176).  Field et al used 
hospitalisation and medication costs in their analysis. Medication costs were defined as “the average 
wholesale cost on the day they were dispensed”(183). Hoonhout et al included medication costs as a 
subgroup of hospitalisation costs. Medication costs were obtained from “Dutch guideline prices” for 
hospitals (168) . Meissner et al also included medication costs within hospitalisation costs. The 
method of establishing costs specific to medication is not explicitly stated (181). Pinilla et al also 
included medication costs within hospitalisation costs. Overall costs were derived from the hospital 
accounting system but how costs specific to medication were calculated was not specifically stated 
(172). Ranchon et al used medication cost in combination with hospitalisation cost. Medication cost 
pertained to cost of anti-neoplastic agents.  It was implied but not explicitly stated that medication 
cost was derived from French public health insurance data (178).  
Costs for particular class of medication were provided in three of the included studies namely 
vaccines, inhaled medications and oxycodone (173, 174, 176). No other study specified the type of 
medication being costed. 
3. Primary care costs:  
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Direct costs specific to primary care were calculated in two studies. Al-lela et al costed the time of 
primary care physicians, nurses and administrators in providing erroneous childhood immunisations 
in public health clinics in Iraq. Salary information was obtained from the Department of Health in 
Iraq (176). The errors identified occurred in primary care and the subsequent cost consequences 
were costs incurred in primary care. As previously described, Field et al included physician fee, 
diagnostic tests, lab tests, home health visits, medical equipment and ambulance costs in their 
analysis of the economic impact of pADEs among ambulatory elderly patients in the USA. It was 
unclear if the errors identified occurred in primary care or in the hospital setting.  Separate primary 
care costs were not available in this study r as the economic impact reported was a combination of 
both hospital and primary care costs (183).   
4. Outpatient care costs: 
Direct costs pertaining to outpatient care were calculated in three studies. All three studies used 
health insurance database information when calculating costs.  Field et al included costs pertaining 
to physician fee, diagnostic tests, laboratory tests and medical equipment (183). Hellinger et al 
calculated costs pertaining to services and physicians fees in outpatient facilities but did not provide 
a breakdown of what the services included (179). Lahue et calculated costs pertaining to post 
discharge physician services but did not specify what the services included (177).  
Non-healthcare costs: 
One of the included studies calculated costs that were not related to the provision of healthcare but 
rather to health-professional litigation costs associated with medication error (180). 
1. Litigation costs:  
Litigation costs, defined as the cost of clinical claims made against the National Health Service (NHS) 
in the UK regarding medication errors during anaesthesia, were used in a single study and were used 
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as an isolated measure of economic impact. Cost information was obtained from the NHS litigation 
authority database (180).   
Economic impact of medication error: 
Thirteen of the included studies expressed economic impact in monetary terms with one study (182) 
using length of hospital stay as the primary outcome measure.  The economic impact of medication 
error calculated by the different studies varied considerably.  
Five of the included studies reported a cost for medication errors associated with harm (168, 171, 
177, 180, 182, 183), four studies reported a combined cost for medication errors associated with 
harm and without harm (169, 170, 172, 181) and three studies reported costs for intercepted 
medication error (173, 175, 178).  
Cost per medication error was extracted from 12 of the included studies: see Table 4. A cost per 
error for general medication error was available in five of the included studies (168-172). The other 
seven costs per error pertained to individual types of medication error or medication error within a 
specific population (173, 175, 176, 178, 180, 181, 183).  Mean cost per error per study ranged from 
€2.58 to €111,727.08. The lowest costs per error were those associated with unnecessary and invalid 
immunisations in children (176) and the highest costs per error were litigation costs associated with 
medication errors during anaesthesia (180). 
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Table 2 4:  Reported economic impact and cost per medication error 
Study Reported economic impact Cost per error (Euro 2015) 
General medication error  
 
17.6/16.7*  
*Figures from 2 different 
mathematical models 
Choi (169) Cost of  470 medication errors 
among hospital inpatients: 
Samp (170) Cost per pADE 86.13 
Pinilla (172) For 62 medication errors 
among hospital inpatients: 
Cost 
Excess length of stay 
2,184.93/1510.15 
(mean/median) 
Hoonhout (168) Per hospital inpatient with 
pADE: 
1. Excess length of stay 
2. Cost per pADE 
3456.38 
Hughes (171) Per community hospital 
inpatient with pADE: 
1. Excess length of stay 
2. Cost per pADE 
6,432.16/4,659.76 
(mean/median) 
Individual type of medication error within a specific population 
Al-lela (176) Cost of 483 erroneous vaccines 2.58 
Gharekhani (175) Cost of 1372 medication errors 
on a nephrology ward 
5.6 
Zaidi (173) Cost per erroneous inhaler 
prescription 
67.93 
Ranchon (178) For 449 errors among patients 
receiving antineoplastic agents 
Cost 
Excess length of stay 
226.02 
Meissner (181) Cost per medication error 
among inpatients in receipt of 
IV patient controlled analgesia 
827.99 
Field (183) Cost per pADE in ambulatory 
elderly patients 
1, 867.08 
Cranshaw (180) Cost of 62 drug errors in 
anaesthesia 
111,727.08 
pADE=Preventable adverse drug event 
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Types of medication error:  
Cost information on an individual type of medication error was available in 10 of the included 
studies. Meissner et al reported individual costs for errors of communication, name confusion, 
storage, human origin, systems, contraindicated medication, equipment and default respectively 
(181). Four further studies reported the economic impact of prescribing error (173, 174, 179, 182). 
Five of the included studies reported economic impact of pADEs (168, 170, 171, 177, 183).  None of 
the studies reported errors of omission. 
Subgroup analysis:  
Three subgroups were identified and are described in Table 5; firstly, the economic impact of 
prescribing error, secondly the economic impact of pADEs and thirdly the economic impact of 
medication error in elderly patients.  Four of the included studies reported economic impact of 
prescribing error (173, 174, 179, 182). Five of the included studies reported economic impact of 
pADEs (168, 170, 171, 177, 183) . Two of the included studies assessed economic impact of 
medication error in elderly patients (>65 years) (168, 183). Study population and measures of 
economic impact varied between studies. 
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Table 2 5: Subgroups (prescribing error, pADE, medication error in elderly patients) 
Error Study population Measure of economic 
impact 
Reported economic impact  
Prescribing error 
Drug-drug interaction 
(179) 
Patients with HIV Additional annual healthcare 
utilisation cost 
€4274.50 
Drug-drug interaction 
(182) 
Hospital inpatients Increased length of hospital 
stay 
7 days 
Drug duplicaton (174) Patients prescribed 
oxycodone 
Total cost of medication €3,244.97 
Error of preparation, 
strength or dose (173) 
 
Patients prescribed 
inhalers 
Cost per medication error €67.93 
pADE     
pADE (171) Community hospital 
inpatients 
Additional hospitalisation 
costs per pADE 
€6314.35/4574.41 
(mean/median) 
pADE (177) Hospital inpatients 
receiving an 
injectable 
medication 
Additional hospitalisation or 
post discharge physician 
services costs of pADEs: 
1. Per hospital 
admission 
2. Annual cost 
3. Annual inpatient 
cost 
 
 
 
1. €2879.03 
 
2. €3.6 billion 
3. €567,943.22 
pADE (170) Patients in hospital 
and primary care 
Costs of monitoring, 
medication regimen change, 
permanent harm to patient 
per pADE 
€84.56 (€85.31 using 
sensitivity analysis) 
 
pADE >65 years 
pADE (168) Hospital inpatients Additional hospitalisation 
costs per pADE 
1.Patients <65 years 
2.Patients>65 years 
 
 
€3277.29  
€3440.88 
pADE (183) Ambulatory patients 
>65years 
Additional primary and 
secondary health care 
utilisation cost per pADE 
€2599.96 
pADE=Preventable adverse drug event 
 
2.5 Discussion 
 
Studies included in this review assessed the economic impact of medication error in nine different 
countries over an 11-year period (2004-2015). Considerable variability existed between studies in 
terms of study design, study population, types of medication error, cost parameters and financial 
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information sources. Hence meaningful comparison of economic impact between studies was 
limited.  A difference of greater than €100,000 was detected between the lowest and highest costs 
per individual medication error.    Establishing an overall pattern was possible however as all of the 
included studies found medication error to be a significant economic healthcare burden in their 
respective settings with all studies reporting increased financial costs or length of hospital stay. 
Three of the included studies did report a similar cost outcome of additional healthcare utilisation 
costs per pADE. The highest cost of €6314.35/4574.41 (mean/median) was reported in a study 
among inpatients in community hospitals in the USA (171) with lower costs of €3440.88 reported in 
a Dutch study among elderly hospital inpatients (168) and of €2599.96 in an American study among 
elderly ambulatory patients (183). The study reporting the highest cost per pADE used additional 
capital and operating costs in their calculation of hospitalisation cost (171) which may account for 
the difference in cost and may suggest that studies not including such costs are under estimating the 
true economic impact of medication error. The reason for lower costs in the American study among 
ambulatory elderly patients compared to the Dutch study among elderly inpatients may be due to 
the differing countries and healthcare systems. Additionally, the difference may be due to increased 
morbidity among hospital inpatients compared to ambulatory patients hence contributing to greater 
costs.   As only hospitalisation costs are reported in the Dutch study however, the difference could 
also suggest that medication errors among patients in primary care are associated with a lower 
economic burden than those occurring in a hospital setting.   
The review identified that the economic impact of medication error has been predominantly 
explored in the hospital setting and that hospitalisation costs represent the parameter used most 
frequently to establish the economic impact of medication error.  However, variability was detected 
in both the definitions of hospitalisation costs and the sources of financial information used between 
studies.  Additionally, it was identified that limited parameters have been used to date to establish 
economic impact of medication error, with included studies using only four parameters in addition 
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to hospitalisation costs namely; medication costs, outpatient costs, primary care costs and litigation 
costs. Although medication costs were reported for half of the studies, methods to establish 
medication cost were not explicitly stated nor could they be isolated from overall costs reported in 
three of the included studies.  A minority of studies (176, 177, 179, 183) reported outpatient costs 
and costs occurring in primary care.  
The review established that to date primarily healthcare costs have been used to determine the 
economic impact of medication error (168-179, 181-183), with litigation costs being the only 
additional cost parameter used (180). Only two of the included studies conducted more in-depth 
costing of health care related costs through the calculation of hospital operating and capital costs 
(171)and opportunity cost pertaining to missed hospital revenue (181). Hence the true economic 
burden of medication error may have been underestimated to date.   
Economic impact associated with an individual type of medication error could only be extracted in 
five of the included studies (173, 174, 179, 181, 182).  Although four studies reported the economic 
impact of prescribing error and hence provided information on the economic impact associated with 
medication error in a particular health care professional group; namely doctors, the outcome 
measures varied considerably limiting comparison.    
Comparison with previous reviews 
No previous systematic review has examined the economic impact specifically pertaining to 
medication error.  Lassetter et al conducted a literature review on quality of care and cost issues 
pertaining to medical error, drug related problems and medication errors in 2003. Although a 
substantial economic impact was reported, the authors did not distinguish between the economic 
impact of drug related problems and medication error in their review (185). Chiatti et al conducted a 
systematic review on the economic burden of inappropriate prescribing, lack of adherence and 
compliance and adverse drug events in the elderly. Again although a substantial economic burden 
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was identified, the authors did not separate preventable adverse drug events that are consistent 
with medication error from adverse drug events in general (186).  
 Non-adherence to medication and potentially inappropriate prescribing have been included in other 
reviews (185, 186) but were excluded from this systematic review. Non-adherence, may represent 
an intentional decision made by an individual patient rather than the unintentional over or underuse 
of medication i.e. medication error. Inappropriate prescribing refers to the use of a drug where the 
risk of an adverse drug event outweighs the clinical benefit, particularly if a safer or more effective 
alternative therapy is available (37). Potentially inappropriate prescribing refers to such 
inappropriate prescribing as identified by standardised tools such as Beer’s criteria and 
STOPP/START (37). Not all potentially inappropriate medications detected in this manner necessarily 
represent medication error however.  The possibility exists of an intentional and informed decision 
on the part of the prescriber rather than the occurrence of true medication error. 
Overall completeness and applicability of evidence: 
Due to the heterogeneity of the included studies a meta-analysis could not be performed. 
Half of the included studies examined the economic impact of medication error within a specific 
patient group and hence the results may not be generalizable to a general patient population.   
Additionally, the majority of studies used a broad definition of medication error and did not stratify 
individual types of medication error in their cost analysis. Hence the evidence was insufficient to 
identify the types of medication error most likely to result in economic burden or to identify a 
particular group of health care professionals responsible for errors likely to result in economic 
burden. 
 Errors of omission were absent from the included studies. Hence where medication costs are used 
to calculate the economic impact of medication error, the true economic burden may be 
underestimated. 
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None of the studies looked at economic implications from a patient or societal perspective. Indirect 
costs were largely absent from studies to date with no studies considering costs such as loss of 
earnings. Quality of life was not considered in any of the included studies. This is in keeping with the 
findings of a recent review conducted by Patel et al of approaches used for calculating the cost of 
medication errors (187).  In addition, the costs explored from a primary care perspective were 
limited and costs pertaining to time of general practitioners and pharmacists were absent. GPs and 
community pharmacists as accurate providers of patients’ medication information, play a key role in 
reducing medication error (121).  A study conducted in the United Kingdom found that a pharmacist 
involved in dispensing a prescription with errors or missing information spent on average 5.7 
minutes per problem with a range from 0.2-48 minutes (188). A similar time burden amongst GPs is 
likely and would suggest a significant unexplored economic burden. 
Quality of the evidence: 
As methodology varied between studies and details of how cost information was obtained was 
lacking in a number of studies, it is not surprising that a lack of consistency was identified between 
results. An overall absence of high quality studies in this area was highlighted with only one study 
(177) fulfilling all applicable quality criteria. Additionally, reported costs in 3 studies were based on 
potential costs as decided by an expert panel (168, 178, 181). The potential for subjectivity exists 
and evidence from the opinion of expert groups has traditionally been regarded as the lowest level 
in the hierarchy of levels of evidence (189).  
Potential biases in the review process: 
The year of publication was used in 4 of the included studies to inflate costs to 2015 values as no 
year was specified in the studies. This could result in a potential inaccuracy if the cost information 
was in fact obtained in an earlier year. The review was limited to English language publications and 
as grey literature was not sought may also be subject to a publication bias. Assessment of study 
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quality was challenging due to variability in terms of study design of the included studies. The 
approach used for quality assessment was applicable to all of the included studies but only assessed 
quality from economic and error reporting perspectives.  Standardised tools assessing quality from 
an epidemiological perspective could not be applied universally to the studies (159). Additionally, 
other checklists for critical appraisal of economic studies pertained specifically to economic 
evaluations and could not be applied (160, 161). 
Recommendations: 
In order to allow meaningful comparison between studies assessing the economic impact of 
medication error, standardisation in terminology pertaining to medication error is required. Future 
studies should provide additional information on firstly the types of medication error being costed 
and secondly the consequences of   errors in terms of patient harm. The recent EMA guidance on 
recording, coding, reporting and assessment of medication errors has the potential to enhance 
future work in this area (62). Future studies would be strengthened by applying a case-control 
design so that incremental costs can be calculated. Greater detail is also required from an economic 
perspective. Clear descriptions of cost sources and explicit cost calculations are required as 
recommended by Patel et al in their recent review of approaches for calculating the cost of 
medication errors (187). Additionally, the timeframe during which the costs are calculated should be 
specified. A greater breadth of costs also needs to be explored in future studies.  Direct costs, 
indirect costs and psychosocial costs should all be included to determine the true economic burden 
of medication error.  
 
2.6 Conclusion 
This systematic review suggests that the true economic impact of medication errors has not been 
accurately estimated to date. Studies evaluating the economic impact of medication error have been 
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primarily conducted among hospital inpatients and have focused mainly on the hospitalisation costs 
associated with medication error. Information on the cost of medication error in primary care or at 
the primary secondary care interface is limited. Restricted parameters were used to establish cost 
with limited information on costs such as healthcare professional time. Variability was detected in 
methodology and many studies were of poor quality. Future work is required firstly to assess the 
economic impact of individual types of medication error and secondly to assess economic impact in a 
broader context inclusive of primary care, patients and society.  
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5.DISCUSSION 
 
5.1 Summary of findings 
 
Medication error is associated with morbidity, mortality and economic burden and is of particular 
concern at the primary secondary care interface as patients move between hospital and the 
community (1, 3, 8). Developing interventions to reduce medication error at this interface in care is 
an international priority (2). The overarching aim of this research was to explore the cost, causes and 
consequences of medication error at the primary secondary care interface in order to develop an 
intervention focused on its reduction.  The MRC  framework for the development of complex 
interventions provided  a systematic, evidence based approach for intervention development (150). 
Research evidence on the cost of medication error was systematically reviewed and synthesised. An 
existing intervention to reduce medication error was examined. Findings from these studies were 
used to inform the development of a pragmatic novel intervention; namely a patient held electronic 
medication record. A detailed theoretically informed evaluation of the feasibility of introduction of 
the intervention at the primary secondary care interface was performed. The overall conclusion is 
that the intervention developed has the potential to reduce the occurrence of medication error and 
its associated morbidity, mortality and economic burden, not only in Ireland, but across healthcare 
systems worldwide.    
 
Establishing an accurate estimate of the cost associated with medication error was the first step in the 
process of intervention development. When conducting an economic evaluation of a quality 
improvement intervention in healthcare the identification, measurement and valuation of both the 
relevant costs and the relevant benefits is required (155). In the case of interventions developed to 
reduce medication error, reduction of the economic cost associated with the error is a major potential 
benefit. A narrative synthesis of the existing literature on the economic impact of medication error 
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identified a lack of information on the cost of medication error in primary care or at the primary-
secondary care interface.  In addition, limited parameters were used to establish economic impact. 
Healthcare cost incurred in relation to hospitalisation was the main, and often the only, parameter 
used in the included studies. It has previously been established that medication error is associated 
with economic burden (18, 33). Chapter 2 finds that, although considerable financial cost has been 
documented with estimates of cost per error as high as €111,727.08 (180), the true economic impact 
of medication error could in fact be greater should additional cost parameters (such as costs pertaining 
to primary care, patients and society) be considered.  
 
Medication reconciliation is an existing process employed to reduce medication error at the primary 
secondary care interface. To gain a better understanding of the process in terms of reducing 
medication error, an existing medication reconciliation process in one institution was examined 
(Chapter 3). Medication reconciliation is widely advocated by professional and accrediting bodies.  
Concerns however, have been expressed recently regarding the resource intensity of medication 
reconciliation and whether it is cost effective in the absence of definitive evidence of the expected 
reduction in healthcare costs (136, 147). Chapter 3 sought to identify factors associated with an 
increased time (and hence economic) burden for medication reconciliation and to determine 
whether there was an association between increased time and detecting errors of clinical 
significance. Issues pertaining to communication of medication information at the primary 
secondary care interface were noted to contribute to a time burden and an association between 
records of medication held by patients and increased time was also described. No association was 
found between spending additional time and capturing errors of clinical significance. This novel 
finding suggests that time intensive medication reconciliation may not be generating cost savings in 
terms of reducing medication error. Further work to establish the potential cost of errors captured is 
required however.   Furthermore, additional time for medication reconciliation may even be 
contributing to economic burden within the healthcare system due to cost incurred in terms of 
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healthcare professional time.  These findings highlight the need to enhance process efficiency for 
cost-effective and sustainable implementation of medication reconciliation, whereby the time 
invested yields the greatest amount of clinical benefit or the process is so time efficient it could be 
implemented universally. Process efficiency could potentially be enhanced by addressing the issues 
identified in relation to records of medication held by patients and communication of medication 
information at the primary secondary care interface.  
 
An intervention, a patient held electronic medication record (the PHARMS device), was developed 
(Chapter 4) as a novel method of communicating medication information between primary and 
secondary care aiming to reduce medication error and the associated economic impact.  Introducing 
the PHARMS device at the primary secondary care interface was shown to be technically 
implementable and acceptable to key stakeholders (namely patients, GPs, IT professionals and junior 
doctors) (Chapter 4). The device (using basic USB technology) was successfully integrated into 
existing electronic systems in primary and secondary care and medication information was 
successfully transferred between sites. Initial technical issues pertaining to the hospital firewall, GP 
server and hospital hardware were resolved during the course of the study.  Lower total error 
number and clinical significance scores among intervention patients compared to control patients 
suggests potential to reduce the occurrence of medication error and hence its associated economic 
burden. The PHARMS device may provide a viable solution to the current issue of medication error 
at the interface of primary and secondary care.  
 
5.2 Where findings fit in the literature 
 
While there is evidence of the effectiveness of interventions to improve the suboptimal use of 
medicines, the evidence of cost-effectiveness is significantly more limited (278, 279). A recent 
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evidence synthesis did not find medication reconciliation to be a cost effective intervention (136). 
Chapter 2 finds that all costs associated with medication error may not yet have been considered. An 
underestimation of the true cost of medication error could therefore account for the lack of cost-
effectiveness evidence of interventions focused on its reduction. Chapter 3 supports existing 
literature finding medication reconciliation to be time and resource intensive (147). In terms of 
increasing time spent on medication reconciliation, an associated economic burden in terms of cost 
of healthcare professional time was described but cost savings in terms of capturing errors of clinical 
significance were not identified. This may offer a further explanation as to why medication 
reconciliation has not been found to be cost-effective in the literature to date. 
 A systematic review established that most medication errors stem from a lack of effective 
communication between health care providers during transitions of care (280) and improving 
communication has been identified as a key strategy in improving overall transitional care (281).  
Poor communication of medication information between primary and secondary care at hospital 
admission was identified as an issue in Chapter 3.  In addition, when interviewed during the 
feasibility study, GPs, patients and junior doctors all described experiencing difficulty with 
communication of medication information between primary and secondary care, not only at hospital 
admission but also at discharge (Chapter 4).  Both hospital admission and discharge have been 
identified in the literature as transitions in care where medication errors are likely to occur. Some 
studies suggest hospital admission as the most critical point for occurrence of error, with others 
suggesting hospital discharge but no consensus exists (279) (107). This thesis finds the occurrence of 
medication error to be a continuum across the primary secondary care interface, including the 
transitions of both hospital admission and discharge, and highlights the need to provide accurate 
medication information to the next healthcare provider in the chain (Chapters 3 and 4). A key finding 
from the feasibility study was the improved communication of medication information associated 
with use of the PHARMS device at hospital discharge.  
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The patient has been identified as having an important role at the primary secondary care interface. 
It has been suggested that to successfully address the issues at the primary secondary care interface, 
health care providers need to view  the system from the patients’ perspective (282) and that 
patients need to be involved in the  transmission of medication information between the different 
levels of care (279).  This work also identifies and supports the role of the patient as a constant 
within transitional care (Chapter 4).  
Benefit has previously been associated with patient held healthcare records and it is now over 10 
years since a review outlining the potential of electronic personal health records to improve patient 
care was published (283). Implementation of such records has not materialised across healthcare 
systems however. Poor integration with existing electronic systems and non-user friendly design 
have been identified as issues (284, 285). Acceptability of electronic personal health records to 
patients has been highlighted as key to successful use (286). In addition, it has been identified that 
to be actually useful, such a record needs to be dynamic rather than being  a static container for 
data (284). The PHARMS device was found to be an acceptable, active, record of medication that has 
the ability to successfully integrate into existing systems and hence has the potential to succeed 
where other personal electronic records have failed.  Acceptability to healthcare professionals is also 
required for universal adoption. Although the PHARMS device was universally useful and acceptable 
to GPs, junior doctors expressed concerns in relation to lack of time, workload and lack of perceived 
relevance. Such issues have previously been identified as barriers in research pertaining to EHR 
implementation (287-289). The lessons learned from EHR implementation in terms of need for full 
involvement of clinical staff, leadership and training (290) were also found to apply to the PHARMS 
device (Chapter 4). 
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5.3 Implications for research 
 
 A commentary on the landmark “To Err is Human” report stated: “If medication errors were a single 
disease we would be investing more heavily. Research funding for cancer is in the billions, yet the 
proportion of people who suffer from medication errors is far greater than those with cancer”(291).  
 
Further research in the area of medication error is warranted and, in particular, research is required 
to explore the economic impact of medication error. Accurate information on the cost of medication 
error is required for cost benefit analysis of all interventions facilitating its reduction. Studies 
examining the economic impact of medication error were found to be of poor quality and to 
evaluate economic impact using limited parameters.  There is a need for future robust, high quality 
costing studies looking at a broader spectrum of costs associated with medication error inclusive of 
primary care, patient and societal costs.  
 
In Chapter 3, although patient harm was prevented through the identification of errors of clinical 
significance in almost half of the study sample, inefficiency and resource intensity associated with 
medication reconciliation were also identified. The PHARMS device has the potential to facilitate 
medication reconciliation by providing access to a list of a patient’s pre-admission medications as 
documented in their GP record. Use of the PHARMS device during medication reconciliation at 
hospital admission has the potential to positively impact process efficiency. A process which is more 
time (and hence cost) efficient may enable widespread and sustainable implementation of 
medication reconciliation.  Further evaluation is warranted in this context.    
 
Reason’s model for error outlines two approaches: the person and the system (292). This thesis finds 
that both the person and the system should also be considered in implementation of an intervention 
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to reduce error. Difficulties with intermittent use of the PHARMS device and the need for 
widespread implementation were identified by GPs and junior doctors during the feasibility study. A 
reluctance to use the device was also reported by junior doctors. Working with clinicians sceptical of 
technology was shown to be of benefit in promoting adoption of the EHR (287, 290). In addition, 
recent evidence suggests successful implementation of electronic tools to support medication 
reconciliation requires stakeholder involvement in terms of design and implementation features 
(293, 294). Further evaluation of the PHARMS device requires engagement; not only of doctors, but 
also of pharmacists as this key stakeholder group was absent from the initial assessment of 
feasibility.  
 
5.4 Implications for practice 
 
The WHO has identified a number of strategies to reduce medication error during the transitions of 
care.  These strategies include;  improved quality and timeliness of discharge information, 
establishing effective medication reconciliation practices, increasing the involvement of primary care 
physicians, improving the effectiveness and timeliness of clinical handovers between clinicians and 
educating and supporting patients, families and carers (102, 295). The PHARMS intervention 
provides a potential method of reducing medication error during the transitions of care with 
multiple benefits across these key areas. Due to its use of basic universally applicable USB 
technology, the PHARMS device has the potential to positively impact international clinical practice. 
  
A national clinical incidents report published in 2017 highlighted the prevalence of medication error 
across the Irish Healthcare system. The need for an EHR which would work seamlessly between the 
hospital and the community was emphasised. The report stated: “While awaiting the national roll 
out of an Electronic Health Care Record, the linking of IT systems between hospital and the 
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community and GP from a medication viewpoint would be useful”(29) . The same report cited the 
need for “empowerment of the patient/carers/family to become active participant(s) in the 
multidisciplinary team, particularly at the transitions of care which are the times of high risk”. The 
PHARMS device has the potential to meet the immediate need identified as currently existing within 
the Irish healthcare system.  
 
It has been identified that care transitions may provide an opportunity in terms of appropriate 
medication use and adherence (52). The practice of medication reconciliation harnesses this 
opportunity but resource intensity is currently a barrier to universal implementation. Guidance 
provided by HIQA on medication safety in Irish hospitals produced in 2018 states the need to  
“develop a national approach to advance medication reconciliation to include defining responsibility 
for medication reconciliation and using electronic solutions to reduce time spent by clinical staff on 
medication reconciliation”(143). The PHARMS device may have a role in assisting with pharmacist 
led medication reconciliation in terms of enhancing process efficiency for widespread and 
sustainable implementation.   
 
 Having identified that medication error occurs across a continuum of the primary secondary care 
interface, in order to successfully address this issue we should also view primary and secondary care 
as a continuum with a single multidisciplinary healthcare team. The healthcare team should include 
the patient in addition to healthcare professionals from both primary and secondary care. As the 
patient is the one constant in transitional care and the GP as has a central role in overall patient 
care, the PHARMS device has the potential to harness the strengths of individual team members.  
The device also has the potential to improve clinical handover between members of such a 
multidisciplinary team in both the community and hospital.  
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5.5 Implications for policy 
 
At a policy level the need to move towards a primary care centric health care system has recently 
been highlighted nationally and internationally (2, 100). The Irish Department of Health Slaintecare 
report published in 2017 has called for significant investment in primary care (2, 100).  It has 
previously been suggested however that, as outlined in Figure 6.1 , the most evolved form of 
healthcare is patient driven and patient centric (247). The innovative use of technology has been 
identified as having the potential to improve efficiency and safety within the Irish healthcare system  
(296). Patient held technology has the potential to create patients who can be active partners within 
the healthcare system, and (in line with the New Haven Recommendations) be involved at the 
micro-level of direct service provision, rather than being merely passive recipients of healthcare 
(297). In terms of medication safety the WHO has highlighted that, in addition to medication 
reconciliation at points of transition, the patient medication record in primary care is of particular 
importance, especially when patients seek treatment from multiple health care providers (53). The 
patient also has a role in contributing to medication safety (298).The PHARMS device is currently 
patient held but does have additional potential to provide the patient with future electronic access 
to their medication information. Finding from this research suggest that, in terms of medication 
management, a patient held technology using medication information originating in primary care in 
the form of the PHARMS device may facilitate care that is both primary care and patient centric.  
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Figure 5 1: Policy vision of health care (284).  
 
 
The need for cost savings and increased efficiency across healthcare systems is widely recognised. 
This thesis suggests a number of areas for potential cost savings in healthcare.  Firstly, the findings of 
the systematic review suggest that reduction of medication error would result in significant cost 
savings (Chapter 2) and that medication error may be reduced by the novel intervention developed 
(Chapter 4).   Secondly, reducing the time spent by healthcare professionals on inefficient processes 
relating to clarification of medication information in secondary care was shown to have the potential 
for substantial cost savings (Chapter 3). A recent report produced by the Department of Health in 
Ireland outlines the need for improved  efficiency in general practice and identified transcribing 
prescriptions and issues pertaining to prescribing as a particular source of inefficiency (10). It is likely 
that savings could also be made in terms of cost of GP’s time, in line with the findings of Chapter 3, 
by improving process efficiency in relation to communication of medication information at the 
primary secondary care interface. Finally, a reduction in healthcare costs has previously been 
associated  with patient empowerment (284) and the PHARMS device may promote such 
empowerment as previously described . 
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Financial incentives have been key to both successful implementation of strategies to reduce 
medication error (299) and to implementation of EHR systems internationally (290) (283). The 
Money Follows the Patient (MFTP) funding model introduced in Ireland in 2014 aims to support 
patient centred care and to “create incentives that encourage treatment at the lowest level of 
complexity that is safe, timely, efficient, and is delivered as close to home as possible” (111) Utilizing 
the aforementioned cost savings to generate financial incentives to promote implementation of this 
novel intervention would therefore be in line with current policy.   
 
Based on  evidence supporting the usefulness of a clearly laid out summary of  research findings for 
policy makers (300), a policy brief was prepared  based on the findings of this thesis and presented 
at a meeting with the HSE IT manager for primary care in Ireland (Appendix 3). 
 
 
5.6 Strengths and limitations 
 
The strengths and limitations of the individual studies are outlined in Chapters 2 to 4 respectively.  
 
Strengths 
The major strength of this thesis was the use of MRC guidance to develop a novel intervention in a 
robust and structured manner, drawing on existing evidence, establishing new evidence and utilising 
appropriate theory. A further strength was involvement of a multidisciplinary team who provided 
diverse skills and views during the course of this research. The input of both a practicing clinician and 
a commercial provider of GP software throughout intervention development helped maintain a 
pragmatic focus thus potentially avoiding difficulties previously highlighted in the literature relating 
to implementing findings from research into clinical practice (301). Employing qualitative and 
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quantitative methodology was a further strength with the end product of this thesis being evaluated 
in a robust and detailed manner.  An additional strength is conducting the cross-sectional and 
feasibility studies of this thesis among a general population of older adult patients without 
significant exclusions. This, in addition to the study findings being supported by existing literature in 
terms of occurrence of medication error, may suggest that the novel findings of the thesis are 
applicable to a general older adult population.  
               Limitations 
The overall numbers of patients included in the cross-sectional and feasibility studies of the thesis 
are small. A further limitation is that the studies included older adult patients in a single 
geographical location and involved a single hospital. Further research is required involving greater 
patient numbers, more diverse geographical locations and multiple clinical sites. An additional 
limitation of this work is that initial assessment of feasibility of the intervention did not involve 
pharmacists. As pharmacists are key stakeholders in terms of medication error and medication 
reconciliation, future work involving this group is required. A final limitation is that my background 
as a clinician in general practice may have influenced my interpretation of findings throughout the 
thesis. I sought however to involve those in other disciplines including public health, pharmacy, 
economics and IT at all points during this work to assist in developing a broad and balanced 
interpretation of results. 
5.7 Conclusion 
 
Medication error is an important patient safety issue and developing interventions focused on its 
reduction is currently an international priority. An accurate estimate of associated economic burden 
is required to inform the successful development and implementation of such interventions. This 
thesis suggests that the true cost of medication error may not, so far, have been accurately 
estimated. Medication reconciliation, as an established intervention to reduce medication error, 
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lacks evidence in terms of cost effectiveness. This may result, in part, from a time burden incurred 
due to inefficiencies relating to lack of available and accessible medication information at the 
primary secondary care interface, but also potentially from the true cost of medication error being 
underestimated. The novel patient held electronic medication record developed and evaluated 
during the course of this thesis addresses an important cause of medication error; poor 
communication of medication information at the primary secondary care interface. As a 
consequence, it has the potential to both reduce medication error at the primary secondary care 
interface and to improve process efficiency of medication reconciliation with implications for 
significant cost savings in healthcare. 
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APPENDIX 1: Supplementary material for Chapter 2 
 
 
An update to the systematic review 
 
A further search of all databases included in the original search was conducted in November 2018.  
PubMed, Cochrane, Embase, CINAHL, EconLit, ABI/INFORM and Business Source Complete were 
searched to identify papers published between April 2016 and November 2018. The same search 
strategy used in the original systematic review (as outlined in this appendix) was utilised. Search 
results from the multiple databases were transferred to a reference manager (End Note). 
 
 Results:  
The search yielded 1007 titles for review. Reasons for exclusion are outlined in Figure A1.1.  
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After searching databases 1007 
titles were reviewed 
At title review stage 893 were excluded. 
Reasons for exclusion: 
 
 152 duplicate papers  
 247 interventions to reduce 
medication error 
 13 other forms of medical error 
 67 no economic aspect 
 78 other economic evaluation 
 306 unrelated to medication error 
 30 guidance policy/education 
 
At the abstract review stage 97 articles were 
excluded. Reasons for exclusion: 
 
 1 intervention to reduce medication 
error 
 55 no economic component 
 22 did not comply with definition of 
medication error (e.g. included non-
adherence) 
 12 commentary or editorial 
 1 research in progress 
 6 conference abstracts 
 
14 papers were excluded following review of 
full text. Reasons for exclusion: 
 2 conference abstracts 
 3 reviews or commentaries or case 
reports 
 2 inadequate economic information 
 7 did not comply with definition of 
medication error 
 
114 articles underwent abstract 
review 
17 papers underwent full text 
review 
 
 3 papers were eligible for 
inclusion  
 
Figure A 1 1: Reason for exclusion of studies 
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A summary of the studies which met inclusion criteria is listed in Table A1.1. The studies were conducted in the USA (n=1), Europe (n=1) and Canada (n=1). 
Table A 1 1 Summary of studies meeting inclusion criteria 
 
First 
author 
Year 
 
Title 
 
Study design 
 
Methods used to 
identify  
medication errors 
 
Study 
population 
 
Study 
setting 
 
Sample 
size 
patients 
 
Sample 
size  
errors 
 
Type of medication 
error 
 
EMA Classification* 
 
Economic 
method 
 
 
Outcome 
measure 
 
Results 
McCarthy 
(302) 
2017 
Medication errors 
resulting in harm: Using 
chargemaster data to 
determine association 
with cost of 
hospitalization and length 
of stay 
 
Case control: 
Retrospective review 
of voluntary error 
report data using 
diagnosis codes  
 
Hospital in 
patients 
(secondary 
/tertiary 
care), USA 
 
3,521 
 
242 
 
Medication error that may 
have contributed to or 
resulted in temporary 
harm to the patient and 
required intervention 
Errors with harm  
 
Measuring of 
direct costs  
 
In case and control 
groups: 
1.Length of stay 
2.Cost of 
hospitalisation 
 
Economic impact of 
errors potentially 
associated with harm 
1.Median LOS: 
Case 5.0 (5.0-11.0) 
Control 5.0 (4.0-7.0) 
2.Median Cost 
Hospitalization: 
Case $19,444 (13,481-
40,580) 
Control $17, 173 
(12,500-27,125) 
(Additional information 
on 5 subgroups; 
antineoplastics, 
corticosteroids, opiates, 
Patients >65yrs, <65 
years) 
Amelung 
(303) 
2017 
Association of preventable 
adverse drug events with 
inpatients’ length of stay-
A propensity matched 
cohort study 
Case control (using 
propensity score): 
Retrospective review 
of medical records  
 
Hospital in 
patients 
(secondary 
/tertiary 
care), 
Germany 
4,462 220 pADE** as defined by 
predetermined list of ICD-
10 codes  
Errors with harm 
Measuring of 
direct costs  
 
Excess length of 
stay 
Economic impact of 
errors associated with 
harm: 
Additional LOS incurred 
by cases: 
Increased LOS of 1.88 
days 
Tchouaket 
(304) 
2017 
The economic burden of 
nurse-sensitive adverse 
events in 22 medical-
surgical units: 
retrospective and 
matching analysis 
Case control (using 
propensity score): 
Retrospective review 
of medical records  
 
Hospital in 
patients 
(secondary 
/tertiary 
care), Canada 
 
4,699 29 pADE** 
Errors with harm 
Measuring of 
direct costs 
(costs 
established from 
literature 
review) 
Hopsitalization 
costs (as 
established from 
literature review) 
Economic impact of 
errors associated with 
harm:  
Additional costs incurred 
by cases: 
Mean $49.382.4 
Median $42,356.0 
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*European Medicine’s Agency (EMA) Classification:  
 Medication errors with harm 
 Medication errors without harm 
 Intercepted medication errors 
 Potential medication errors 
**pADE: Preventable Adverse Drug Event 
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Table A1.2 outlines the parameters used to assess study quality. The viewpoint was explicitly stated 
in one study (304) but could be implied by the cost data used in the other studies. The study 
population was described (though in varying detail) in all studies and a clear description of the costs 
used in the analysis was provided in all studies. Discounting was not applied to one study, was not 
applicable to another and was correctly applied in the third. All three studies measured incremental 
costs and reported costs as per the EMA guide. One study fulfilled all applicable quality criteria.  
 
Table A1 2: Assessment of study quality 
Study Viewpoint Population Relevant 
costs 
Discounting Incremental 
costs 
Sensitivity 
analysis 
Costs reported 
as per EMA* 
guide 
McCarthy 
(302) 
[+] + [+] 0 + 0 + 
Amelung 
(281)  
[+] [+] [+] N/A + 0 + 
Tchouaket 
(304) 
+ + [+] + + + + 
Notation based on Rothfuss et al (184): +, present; [+], partly fulfilled; 0, absent. N/A, non-applicable 
*EMA: European Medicines Agency 
 
All three studies applied a case control design and were conducted among a general population of 
adult hospital inpatients.  
 
Methods and parameters used to establish economic impact 
The three studies measured direct costs pertaining to medication errors to which the study 
population was exposed. Indirect costs were not measured.  
The three studies calculated costs associated with hospitalisation and all demonstrated an increased 
economic burden associated with medication error.  
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Two studies expressed economic impact in monetary terms (302, 304) with one study expressing 
economic impact in terms of increased length of hospital stay (303). One study expressed economic 
impact in both monetary terms and in terms of increased length of hospital stay (302). 
Of the studies expressing economic impact in monetary terms one used information from the 
hospital accounts system (302) and one used costs taken from a review of the literature (304).  
McCarthy et al state using “total hospitalisation cost” information for each patient (302). Tchouaket 
et al define hospitalisation costs as “hospital related treatment costs due to the prolongation of 
hopsitalisation by the event” (304). No breakdown of overall hospitalisation cost is giving in any of 
the included studies. 
 
Economic impact of medication error 
Two of the studies provided information on the economic impact of pADEs. McCarthy et al provided 
an overall estimate of cost of medication errors with the potential to cause harm in case and control 
groups, in addition to providing information on cost of medication error for five subgroups namely; 
antineoplastic medication, corticosteroid medication, opiate medication, Patients >65yrs, and 
patients <65 years.  
 
Discussion: 
All studies reported increased financial costs or length of hospital stay associated with medication 
error and confirm that medication error is associated with a significant economic burden. All studies 
were conducted among hospital inpatients, and cost of hospitalisation was the only parameter used 
to establish economic impact. Limited detail was provided from an economic perspective and costs 
from a primary care, patient and societal perspective were absent.   
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The findings of the updated search support the original findings of the systematic review and there 
were no new findings.  
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Search strategy 
 
Pubmed 
(Cost OR Cost analysis OR Econ*) 
 AND 
 (Medication error OR Inappropriate Prescribing OR” Inappropriate Medication” OR Preventable 
adverse drug event* OR Preventable adverse drug reaction* OR Prescribing error* OR Transcription 
Error* OR Medication Discrep* OR Medication omission*) 
Limit: 01/01/2004 to present, English 
CINAHL 
(Cost OR Cost analysis OR Econ*) title and abstract 
AND 
 (Medication error OR Inappropriate Prescribing OR” Inappropriate Medication” OR Preventable 
adverse drug event* OR Preventable adverse drug reaction* OR Prescribing error* OR Transcription 
Error* OR Medication Discrep* OR Medication omission*) 
Limit: 01/01/2004 to present, English 
Econlit 
(Cost OR Cost analysis OR Econ*) 
 AND 
 (Medication error OR Inappropriate Prescribing OR” Inappropriate Medication” OR Preventable 
adverse drug event* OR Preventable adverse drug reaction* OR Prescribing error* OR Transcription 
Error* OR Medication Discrep* OR Medication omission*) 
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Limit: 01/01/2004 to present, English 
Business Source Complete 
(Cost OR Cost analysis OR Econ*) 
 AND 
 (Medication error OR Inappropriate Prescribing OR “Inappropriate Medication” OR Preventable 
adverse drug event* OR Preventable adverse drug reaction* OR Prescribing error* OR Transcription 
Error* OR Medication Discrep* OR Medication omission*) 
Limit: 01/01/2004 to present, peer reviewed journals, English 
Embase 
 ('Cost'/exp OR Cost OR Costs OR ('Cost'/exp OR Cost AND ('Analysis'/exp OR Analysis)) OR 
Econ*) title and abstract 
AND 
'Medication'/exp OR Medication AND ('Error'/exp OR Error) OR (Inappropriate AND Prescribing) 
OR 'Inappropriate Medication' OR (Preventable AND Adverse AND ('drug'/exp OR drug) AND 
event*) OR (Preventable AND Adverse AND ('drug'/exp OR drug) AND Reaction*) OR 
(Prescribing AND Error*) OR (Transcription AND Error*) OR ('Medication'/exp OR Medication 
AND Discrep*) OR (Medication AND Omission*) title and abstract 
Limit: 01/01/2004 to present, Human, English 
ABI/INFORM 
(Cost OR Cost analysis OR Econ*) title and abstract 
 AND 
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 (Medication error OR Inappropriate Prescribing OR” Inappropriate Medication” OR Preventable 
adverse drug event* OR Preventable adverse drug reaction* OR Prescribing error* OR Transcription 
Error* OR Medication Discrep* OR Medication omission*) title and abstract 
Limit: 01/01/2004 to present, peer reviewed scholarly journals, English 
Cochrane 
Medication error 
AND 
(Cost OR Econ*) 
Limit: 01/01/2004 to present 
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Data Extraction Form: 
 
Table A1 3: Data extraction form 
Author: 
Year and country: 
Title:  
Study setting:  
Study type: 
Study population: 
Study sample size 
Type of medication error: 
Economic method: 
Outcome measure: 
Results:  
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PRISMA statement: 
 
Table A1 4: PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  40 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
41,42 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  43 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
44 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
44 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
45,46 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
44 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
44 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
45,46 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
46 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
46 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
47,48 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  48 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
48 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
48 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
48 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
50 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
51-56 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  57 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
51-56 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  58-65 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  57 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  67 
DISCUSSION   
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
67-69 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
71 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  72,73 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
N/A 
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Inflating retrospective costs using the Consumer Price Index (CPI): 
 
1. CPI:  www.tradingeconomics.com  
 
Formula: Guidelines for the Budget Impact Analysis of Health Technologies in Ireland. Health 
Information and Quality Authority.www.hiqa.ie/publications/guidelines 
(Latest CPI/Earlier CPIx100) -100=percentage price increase 
Currency conversion: www.x-rates.com Nov 2015 
 
2. Percentage price increase for each study:  
 
 Al-lela Iraq 2012-2015: (149.7/141x100): 6.17% 
 Choi USA 2013-2015: (237.6/232x100): 2.41% 
 Cranshaw UK 2009-2015: 128.2/110: 16.5% 
 Field USA 2000-2015: 237.6/170: 39.7% (published 2005 but costs 2000) 
 Gharekhani Iran 2011-2015: 224.4/90: 149.3% (published 2014 but costs 2011) 
 Hellinger USA 2010-2015: 237.6/217: 9.49% 
 Hoonhout The Netherlands 2004-2015: 117.18/97.5: 20.18% (published 2010 but costs 
stated as 2004) 
 Hughes USA 2006-2015: 237.6/198: 20% (published 2012, costs 2006) 
 Lahue USA 2013-2015: 237.6/232: 2.41% (published 2012, costs 2013) 
 Meissner USA 2006-2015: 237.6/198: 20% (published 2009, costs 2006)  
 Moura: No monetary cost 
 Pinilla:  Spain 2001-2015: 102.5/77: 33.12% (published 2006, costs 2001) 
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 Ranchon: France 2008-2015 127.8/117: 9.23% (published 2011, costs 2008) 
 Samp: USA 2012-2015 237.6/230: 3.3% (published 2014, costs 2012) 
 Zahari: Malaysia 2011-2015 113.9/97: 17.4% 
 Zaidi: UK 2013-2015 100/97: 3.09% 
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Prospero registration:   
 
Review registered with PROSPERO 05/08/15 
Registration no: CRD42015024202 
 
 
PROSPERO International prospective register of systematic reviews 
Review title and timescale 
1 Review title 
Give the working title of the review. This must be in English. Ideally it 
should state succinctly the interventions or exposures being reviewed 
and the associated health or social problem being addressed in the 
review. 
The economic burden associated with medication error: a systematic 
review 
2 Original language title 
For reviews in languages other than English, this field should be used 
to enter the title in the language of the review. This will be displayed 
together with the English language title.  
3 Anticipated or actual start date 
Give the date when the systematic review commenced, or is expected 
to commence. 
01/06/2015 
4 Anticipated completion date 
Give the date by which the review is expected to be completed. 
30/11/2015 
5 Stage of review at time of this submission 
Indicate the stage of progress of the review by ticking the relevant 
boxes. Reviews that have progressed beyond the point of completing 
data extraction at the time of initial registration are not eligible for 
inclusion in PROSPERO. This field should be updated when any 
amendments are made to a published record. 
  The review has not 
yet started  
×     
      
Review stage Started Completed  
Preliminary searches Yes No 
Piloting of the study selection process No No 
Formal screening of search results against eligibility 
criteria 
No No 
Data extraction No No 
Risk of bias (quality) assessment No No 
Data analysis No No 
 
  Provide any other relevant information about the stage of the review 
here. 
Review team details 
6 Named contact 
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The named contact acts as the guarantor for the accuracy of the 
information presented in the register record. 
Elaine Walsh 
7 Named contact email 
Enter the electronic mail address of the named contact. 
elaine.walsh@ucc.ie 
8 Named contact address 
Enter the full postal address for the named contact.  
G58, Western Gateway Building, University College Cork, Western Rd, 
Cork 
9 Named contact phone number 
Enter the telephone number for the named contact, including 
international dialing code. 
+353863839492 
10 Organisational affiliation of the review 
Full title of the organisational affiliations for this review, and website 
address if available. This field may be completed as 'None' if the review 
is not affiliated to any organisation. 
University College Cork 
Website address: 
www.ucc.ie 
11 Review team members and their organisational affiliations 
Give the title, first name and last name of all members of the team 
working directly on the review. Give the organisational affiliations of 
each member of the review team. 
  Title First name Last name Affiliation 
Dr Elaine  Walsh Department of General 
Practice, University College 
Cork 
Professor Colin  Bradley Department of General 
Practice, University College 
Cork 
Professor Patricia Kearney Department of Epidemiology 
and Public Health, University 
College Cork 
Dr Laura Sahm School of Pharmacy, 
University College Cork 
Ms Christina Rae Hansen School of Pharmacy, 
University College Cork 
Mr James Gallagher School of Pharmacy, 
University College Cork 
 
12 Funding sources/sponsors 
Give details of the individuals, organizations, groups or other legal 
entities who take responsibility for initiating, managing, sponsoring 
and/or financing the review. Any unique identification numbers 
assigned to the review by the individuals or bodies listed should be 
included. 
None: systematic review being conducted as part of PhD 
13 Conflicts of interest 
List any conditions that could lead to actual or perceived undue 
influence on judgements concerning the main topic investigated in the 
review. 
Are there any actual or potential conflicts of interest? 
None known 
14 Collaborators 
Give the name, affiliation and role of any individuals or organisations 
who are working on the review but who are not listed as review team 
members. 
  Title First name Last name Organisation details 
 
Review methods 
15 Review question(s) 
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State the question(s) to be addressed / review objectives. Please complete a separate box for each 
question. 
To quantify the economic burden associated with medication error 
To identify parameters used to cost medication error 
16 Searches 
Give details of the sources to be searched, and any restrictions (e.g. language or publication period). The 
full search strategy is not required, but may be supplied as a link or attachment. 
PubMed, EMBASE, CINAHL, Cochrane, Econlit, Business Source Complete, ABI/INFORM  
17 URL to search strategy 
If you have one, give the link to your search strategy here. Alternatively you can e-mail this to PROSPERO 
and we will store and link to it. 
 
I give permission for this file to be made publicly available 
Yes 
18 Condition or domain being studied 
Give a short description of the disease, condition or healthcare domain being studied. This could include 
health and wellbeing outcomes. 
Medication error 
19 Participants/population 
Give summary criteria for the participants or populations being studied by the review. The preferred format 
includes details of both inclusion and exclusion criteria. 
Patients in primary, secondary and tertiary care without restrictions with regard to age, gender or ethnicity 
20 Intervention(s), exposure(s) 
Give full and clear descriptions of the nature of the interventions or the exposures to be reviewed 
The exposure to be reviewed is medication error defined as any preventable event that may cause or lead 
to inappropriate medication use or patient harm Inclusion criteria: 1 Errors pertaining to the prescribing of 
medication: Therapeutic and legal errors (e.g. incorrect medication, errors of dose/route/frequency, failure 
to comply with legal requirements of prescribing.) Omissions/discrepancies in the prescribing of 
medication. Transcription error 2 Errors pertaining to the dispensing of medication 3 Errors pertaining to 
the administration of medication Exclusion criteria: Prescribing of potentially inappropriate medications 
Non-compliance or non-adherence to medication. Non-preventable adverse drug reactions  
21 Comparator(s)/control 
Where relevant, give details of the alternatives against which the main subject/topic of the review will be 
compared (e.g. another intervention or a non-exposed control group). 
Not applicable 
22 Types of study to be included initially 
Give details of the study designs to be included in the review. If there are no restrictions on the types of 
study design eligible for inclusion, this should be stated. 
Studies evaluating the economic impact of medication error as defined in Section 20 without restrictions 
pertaining to study design Inclusion criteria: Studies in primary, secondary and tertiary care evaluating the 
economic implications of medication error. Exclusion criteria: Economic evaluations of interventions to 
reduce medication error. Studies evaluating non-medication related error e.g. device implantation Studies 
comparing the costs of the adverse drug reactions of two or more medications.  
23 Context 
Give summary details of the setting and other relevant characteristics which help define the inclusion or 
exclusion criteria. 
Studies in primary, secondary and tertiary care including ambulatory and inpatient settings. 
24 Primary outcome(s) 
Give the most important outcomes. 
1. To quantify the cost associated with medication error 2. To identify what costs are associated with 
medication error and where they are incurred (e.g primary care, hospital, workplace) 3. To review methods 
used when costing medication error. 
Give information on timing and effect measures, as appropriate. 
Direct and indirect costs will be identified. Monetary and other cost measures (e.g. length of hospital stay) 
will be identified.  
25 Secondary outcomes 
List any additional outcomes that will be addressed. If there are no secondary outcomes enter None. 
None 
  Give information on timing and effect measures, as appropriate. 
26 Data extraction, (selection and coding) 
Give the procedure for selecting studies for the review and extracting data, including the number of 
researchers involved and how discrepancies will be resolved. List the data to be extracted. 
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Titles of studies identified from the database search will be reviewed by the primary researcher. 
Subsequent abstract review will be conducted independently by the primary researcher and another 
member of the review team to identify studies that potentially fulfil the inclusion criteria. Full text articles of 
the potentially eligible studies will be obtained and the articles will be reviewed by the 2 researchers. In the 
event of disagreement over the eligibility of the particular studies the articles will be reviewed by a third 
reviewer. Data will be extracted from the studies using a prepared data extraction form. Extracted 
information will include: study setting, study population, patient demographic information. study 
methodology, type of prescribing error, cost data (direct/indirect, monetary/other), information for 
assessment of the risk of bias 
27 Risk of bias (quality) assessment 
State whether and how risk of bias will be assessed, how the quality of individual studies will be assessed, 
and whether and how this will influence the planned synthesis. 
In view of the anticipated heterogeneity of the studies to be included each study will be assessed regarding 
quality and risk of bias on an individual basis. Appropriate assessment tools will be used as per the 
Cochrane Bias Methods Group recommendations.  
28 Strategy for data synthesis 
Give the planned general approach to be used, for example whether the data to be used will be aggregate 
or at the level of individual participants, and whether a quantitative or narrative (descriptive) synthesis is 
planned. Where appropriate a brief outline of analytic approach should be given. 
A narrative synthesis of the studies included will be provided based on the type of medication error, setting 
of the study, population studied and economic burden identified. It is anticipated that there will be limited 
scope for meta analysis due to an expected wide variety of prescribing errors and cost outcome measures. 
However if studies are identified with similar exposure (medication error) and outcome (cost) measures the 
results will be pooled. The results will be assessed for heterogeneity and a random effects meta analysis 
conducted if sufficiently homogenous. 
29 Analysis of subgroups or subsets 
Give any planned exploration of subgroups or subsets within the review. ‘None planned’ is a valid 
response if no subgroup analyses are planned. 
If the necessary data are available subgroup analysis will be conducted by age (65 yrs) and type of 
medication error (e.g. prescribing error) 
Review general information 
30 Type of review 
Select the type of review from the drop down list. 
Other 
Economic, Harm 
31 Language 
Select the language(s) in which the review is being written and will be made available, from the drop down 
list. Use the control key to select more than one language. 
English 
Will a summary/abstract be made available in English? 
32 Country 
Select the country in which the review is being carried out from the drop down list. For multi-national 
collaborations select all the countries involved. Use the control key to select more than one country. 
Ireland 
33 Other registration details 
Give the name of any organisation where the systematic review title or protocol is registered together with 
any unique identification number assigned. If extracted data will be stored and made available through a 
repository such as the Systematic Review Data Repository (SRDR), details and a link should be included 
here.  
34 Reference and/or URL for published protocol 
Give the citation for the published protocol, if there is one. 
Give the link to the published protocol, if there is one. This may be to an external site or to a protocol 
deposited with CRD in pdf format. 
 
I give permission for this file to be made publicly available 
Yes 
35 Dissemination plans 
Give brief details of plans for communicating essential messages from the review to the appropriate 
audiences. 
A paper will be submitted to a leading journal in this field.  
Do you intend to publish the review on completion? 
Yes 
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36 Keywords 
Give words or phrases that best describe the review. (One word per box, create a new box for each term) 
medication error 
cost 
economic 
37 Details of any existing review of the same topic by the same authors 
Give details of earlier versions of the systematic review if an update of an existing review is being 
registered, including full bibliographic reference if possible. 
38 Current review status 
Review status should be updated when the review is completed and when it is published. 
Ongoing 
39 Any additional information 
Provide any further information the review team consider relevant to the registration of the review. 
The findings of this review will be used to inform further research to be conducted as part of the PhD of the 
primary researcher 
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Information on impact of systematic review publication  
 
Web view 
  
 
 
Congratulations — your article was one of our top 
downloaded articles in recent publication history! 
 
 
Dear Elaine Walsh, 
 
We are pleased to announce that your article Economic impact of 
medication error: a systematic review, published 
in Pharmacoepidemiology and Drug Safety, was one of the journal’s top 20 
most downloaded recent papers!*  
 
What this means: 
 Amongst articles published between July 2016 and June 2018, your 
article received some of the highest downloads in the 12-months post 
online publication  
 Your article generated immediate impact and helped to raise the 
visibility of Pharmacoepidemiology and Drug Safety  
Your contributions are vital to growing the profile of Pharmacoepidemiology 
and Drug Safety. 
 
Thank you for sharing in our journal's success, 
The Editors of Pharmacoepidemiology and Drug Safety  
 
* Comparative exercise based on measuring downloads within the first 12 months of online publication, 
for articles published between July 2016 and June 2018  
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APPENDIX 2: Supplementary material for Chapter 3 
 
Clinical Significance of errors: instructions for raters 
 
Definition: this is the degree of patient harm that could be caused by the error. 
Significant: an error that can cause patient symptoms that, while harmful to the patient, poses little 
or no threat to the patient’s life function. 
Serious: an error than can cause signs/ symptoms that are associated with a serious level of risk that 
is not high enough to be life-threatening. In addition, a potential ADE is serious if it can cause 
persistent alteration of daily function. 
Life-threatening: an error that can cause signs/symptoms that if not treated would put the patient 
at risk of death. 
Examples of Severity Categories 
LIFE THREATENING 
Incorrect dose of anti-rejection medication is prescribed in patient with kidney transplant. 
Omission of amiodarone at discharge when given for prevention of ventricular tachycardia. 
Patient with a prior penicillin anaphylaxis reaction and ordered penicillin at admission. 
Incorrect paracetamol dose prescribed at discharge with a total daily dose >15g. 
Omission of warfarin at admission in patient with St. Jude’s mitral valve replacement. 
SERIOUS 
Patients’ correct dose is 2 mg diazepam, doctor prescribes 10 mg on admission. 
Patient with exacerbation of congestive cardiac failure discharged on 1/4 preadmission dose of 
frusemide. 
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Omission of beta-blocker at discharge in patient with coronary artery disease. 
Concurrent paracetamol prescriptions at discharge with a total daily dose >10g but ≤15g. 
Warfarin 5 mg QD prescribed at discharge instead of 3 mg QD (prescribed for atrial fibrillation). 
Indomethacin for gout prescribed at discharge to patient concurrently taking Ibuprofen. 
Omission of lactulose BD in patient with history of hepatic encephalopathy. 
SIGNIFICANT 
Omission of diazepam PRN for insomnia at discharge. 
Change from laxative bisocodyl PRN to bisocodyl BD 
Omission of lisinopril in patient without coronary artery disease, heart failure or valve disease. 
Two concurrent paracetamol prescriptions with a total daily dose >4 grams but ≤10 grams. 
Omission of tramadol PRN for tension headache. 
Additional Examples 
Errors that may lead to hypotension or over-treatment of hypertension are considered to be serious. 
Errors that may lead to under-treatment of hypertension, angina, or ischemia are considered to be 
significant. 
Errors that may lead to significant over-anticoagulation or under-coagulation are considered to be 
serious. 
Errors that lead to under-treatment of asthma are considered to be significant. 
Errors that lead to under-treatment with antibiotics: 
 If IV antibiotics were originally prescribed, consider the errors to be serious. 
 If oral antibiotics were originally prescribed, consider the errors to be significant. 
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Errors that lead to over-treatment with antibiotics: 
 If either IV or oral antibiotics were prescribed, consider the errors to be significant, unless 
the antibiotic is directly toxic to end organs in a highly dose-sensitive fashion (e.g., 
gentamicin), in which case, the severity will be higher (usually serious). 
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Time and motion study 
 
Table A2 1: Time for medication reconciliation 
 
Median
Goal
0
10
20
30
40
50
60
70
80
90
1 2 3 4 5 6 7 8 9 1
0
1
1
1
2
1
3
1
4
1
5
1
6
1
7
1
8
1
9
2
0
2
1
2
2
2
3
2
4
2
5
2
6
2
7
2
8
2
9
3
0
Time 
 Value Median Goal 
1 76 59.5 50 
2 76 59.5 50 
3 71 59.5 50 
4 59.5 59.5 50 
5 59.5 59.5 50 
6 55 59.5 50 
7 55 59.5 50 
8 50 59.5 50 
9 50 59.5 50 
10 55 59.5 50 
11 60 59.5 50 
12 34 59.5 50 
13 50 47.5 50 
14 35 47.5 50 
15 25 47.5 50 
16 50 47.5 50 
17 45 47.5 50 
18 31 47.5 50 
19 56 47.5 50 
20 50 47.5 50 
21 50 47.5 50 
22 40 47.5 50 
23 35 47.5 50 
24 30 47.5 50 
25 50 47.5 50 
26 45 47.5 50 
27 50 47.5 50 
28 40 47.5 50 
29 58 47.5 50 
30 78 47.5 50 
In 2016 the hospital pharmacists conducted an audit of their 
medication reconciliation process. An initial time and motion study 
and established a median time of 59.5 minutes. Following 
implementation of quality improvement measures to the process a 
repeat time and motion study and established a median time of 
47.5 minutes. 
 
Figure A2 1: Time for medication reconciliation 
188 
 
 
Cost of pharmacist time 
 
Table A2 2: Pharmacist salary 
Annual salary scale of basic grade pharmacist (point 7 of 
2017 scale) 
  €47,595  
Employers PRSI +10.75% (Direct Salary Cost) €5116     
Input Pension Cost +4% (Total Salary Cost) €1904     
Overheads +25% (Total Staff Cost) €11899     
Total Cost   €66,514  
Hourly rate (based on that have 9 BH and 27 days annual 
leave i.e.52 -7.2 weeks = 44.8 weeks) 
  €44.93  
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Calculating population growth rate and projected population figures 
 
Formula for calculating population growth rate:  
 
 t: Number of years of census period 
 P2: Population at the end of the census period 
 P1: Population at the start of the census period 
 r: Growth annual rate (in %) 
 
 
Formula for calculating projected population figures: 
 
 t: Number of years 
 P0: Population at the start 
 r: Growth annual rate (in %),  
 Pt: Population after t years 
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STROBE Statement 
 
Table A 2 3: STROBE checklist 
  
 
Item 
No Recommendation 
Page 
No 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
74 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
75,76 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
77,78 
Objectives 3 State specific objectives, including any prespecified hypotheses 79 
Methods 
Study design 4 Present key elements of study design early in the paper 79 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
79,80 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants 
79,80 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
81 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability 
of assessment methods if there is more than one group 
81 
Bias 9 Describe any efforts to address potential sources of bias 81 
Study size 10 Explain how the study size was arrived at 79 
Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
82 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
82,83 
(b) Describe any methods used to examine subgroups and 
interactions 
N/A 
(c) Explain how missing data were addressed 83 
(d) If applicable, describe analytical methods taking account of 
sampling strategy 
82,83 
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(e) Describe any sensitivity analyses N/A 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and 
analysed 
83,84 
(b) Give reasons for non-participation at each stage 83 
(c) Consider use of a flow diagram N/A 
79Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
84 
(b) Indicate number of participants with missing data for each 
variable of interest 
N/A 
Outcome data 15* Report numbers of outcome events or summary measures 84-90 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
87-90 
(b) Report category boundaries when continuous variables 
were categorized 
87-90 
(c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
N/A 
Discussion 
Key results 18 Summarise key results with reference to study objectives 90,91 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
94 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
94,95 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
94,95 
Other information 
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based 
N/A 
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Data collection sheet 
 
 
 
Dressing Knowledge of medications Written record of medications 
   
   
   
   
   
   
   
   
   
   
Study ID Source Admission Time admission Age Gender SES Medication number Comorbidity number Continence Mobility Feeding 
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Study ID Nature of issue requiring additional time Time spent resolving issue (mins) Phonecalls to resolve issue (number) 
    
    
    
    
    
    
    
    
    
    
    
Study ID Drug with error Dose  Frequency Description of error Total error 
number 
Significant error 
number 
Serious error 
number 
Life-threatening 
error number 
Error score 
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APPENDIX 3: Supplementary material for Chapter 4 
 
Consent forms 
 
Patient consent form for participation in research study 
 
Section A: 
Patient Name:     
 
Title of study: PHARMS Study 
 
Doctor Directing Research: Dr Elaine Walsh  Phone: 0863839492 
 
You are being asked to participate in a research study.  The doctors at University College Cork study 
medicines and disease and attempt to develop improved methods of managing patients.  In order to 
decide whether or not you want to be a part of this research study, you should understand enough 
about its risks and benefits to make an informed judgment.  This process is known as informed 
consent.  This consent form gives detailed information about the research study, which will be 
discussed with you.  Once you understand the study, you will be asked to sign this form if you wish to 
participate. 
 
Section B 
I. NATURE AND DURATION OF PROCEDURE(S): 
       We have looked at prescriptions that patients receive when leaving hospital and we have found 
mistakes on the prescriptions. These mistakes have the potential to harm you as a patient and to 
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create difficulty for your GP and pharmacist. We are conducting this study to get more 
information regarding the causes and consequences of these mistakes. We will collect medication 
information from your GP, pharmacy and hospital records and look for mistakes.  We think that a 
list of the medication that your GP normally prescribes for you when you are at home would help 
the hospital doctor when they are writing your discharge prescription. We have developed an 
electronic device that can access your medication information from your record with your GP. 
Your GP can use it and the doctor in the hospital can use it. Some patients in the study will be 
given one of these devices.  If you are given a device we will ask you to hold on to the device when 
you are in hospital and to bring it to any future hospital visits. Only your GP can make changes to 
the list of your medication that can be seen when using this device. The hospital doctor can add 
notes about your medication that your GP will see.  The study aims to check if using this device 
can reduce mistakes on prescriptions leaving hospital and secondly to see if doctors and patients 
find it useful. If you are given a device we will contact you after you go home to conduct and 
interview regarding your experience with it. Data collected is subject to the Data Collection Act  
II. POTENTIAL RISKS AND BENEFITS: 
       The main potential risk for you in this study is that your medication information is being accessed 
and that other people could have access to it. We have taken every precaution when collecting 
information and developing the device to make sure the information is secure and to protect the 
information from being accessed by unauthorized people. 
       The main benefit for you is that mistakes involving your medication will be picked up and rectified 
by your hospital doctors or GP. If you are issued with a device you will have an up to date and 
accurate medication record that is available to any doctor that you might see. It can be used on 
any computer so if you were for example to travel abroad you could bring it with you. If we can 
show that using this device reduces mistakes on prescriptions and that patients and doctors find 
it useful we may be able to improve patient safety nationally and internationally.  
III. POSSIBLE ALTERNATIVES: 
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       Participation in this study is voluntary and you may choose not to participate. 
  
 
Section C                                                                     
AGREEMENT TO CONSENT 
The research project and procedures associated with it have been fully explained to me and no 
guarantee has been given about the possible results.  I have had the opportunity to ask questions 
concerning any and all aspects of the project and the procedures involved.  I am aware that 
participation is voluntary and that I may withdraw my consent at any time.  I am aware that my 
decision not to participate or to withdraw will not restrict my access to health care services normally 
available to me.  Confidentiality of records concerning my involvement in this project will be 
maintained in an appropriate manner.  When required by law, the records of this research may be 
reviewed by government agencies and sponsors of the research. 
I understand that the sponsors and investigators have such insurance as is required by law in the event 
of injury resulting from this research. 
I, the undersigned, hereby consent to participate as a subject in the above described project 
conducted at the Cork Teaching Hospitals.  I have received a copy of this consent form for my records.  
I understand that if I have any questions concerning this research, I can contact the doctor(s) listed 
above.  If I have further queries concerning my rights in connection with the research, I can contact 
the Clinical Research Ethics Committee of the Cork Teaching Hospitals, Lancaster Hall, 6 Little Hanover 
Street, Cork. 
After reading the entire consent form, if you have no further questions about giving consent, please 
sign where indicated. 
 
 
Signature of doctor:____________________________________________ 
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Signature of subject:____________________________________________  
  
         
     
 
Date:                             Time:      AM     PM (Circle)     
         
  
198 
 
IT professional consent form for participation in research study 
 
Section A: 
 
 Name:     
 
Title of study: PHARMS Study 
 
Doctor Directing Research: Dr Elaine Walsh  Phone: 0863839492 
 
 
You are being invited to take part in a research study which is being conducted at the University 
College Cork and the Mercy University Hospital.  
Before you decide whether or not you wish to participate you should read the information provided 
below. You should clearly understand the risks and benefits of participating in this study. Take time 
to ask questions – do not feel rushed or under any obligation to make a hasty judgment. 
You are not obliged to take part in this study. You have the right to withdraw your participation at 
any time (before, during and after the study) for whatever reason without having to justify your 
decision and without negative impact.  
 
Section B 
I NATURE AND DURATION OF PROCEDURE(S): 
 
Why is this study being conducted? 
Medication errors frequently occur during transitional care as patients move between different 
stages and settings of care. Hospital discharge has been identified as a time where medication error 
is likely to occur with negative consequences for the patient, GP and community pharmacist. 
Providing junior doctors with a list of medication taken by a patient pre hospital admission may help 
to reduce error when they generating discharge medication information. Transferring medication 
information between primary and secondary care is challenging. As a potential solution to the 
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problem a patient held electronic medication record has been developed within UCC and is now 
ready to be tested in the clinical setting. This device resembles a key and utilizes the USB port of a 
computer-see image.  
 
 
 
What will your participation involve?.  
You are being asked to participate in an interview which will explore your experience of using the 
device.  
Confidentiality 
The interview will be treated in a confidential manner and your participation is anonymous. The 
interview will be audio recorded so that it can be transcribed afterwards. Your name will not be 
recorded on any information which is collected about you. Instead you will be provided with a 
unique code. The only person with access to the code will be the investigator. The study results and 
anonymized excerpts from your interview may be presented at scientific conferences and/or 
published in an academic journal.  The audio recording will be erased once the interview has been 
transcribed. Transcripts will be stored for 5 years; after which they will be destroyed in line with 
Data Protection legislation. 
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.   
II. POTENTIAL RISKS AND BENEFITS: 
 
What are the possible benefits of participating? 
The use of an electronic patient held medication record may potentially firstly reduce the occurrence 
of patient harm and secondly reduce work load. The information that you can provide from an IT 
perspective will clarify any technological issues arising from the introduction of this device  
Are there any risks of participation? 
It is hoped that no significant negative impact will arise from the study. You will have the option to 
withdraw your participation at any time should you wish.  
  
Section C   
                                                                   
AGREEMENT TO CONSENT 
 
The research project and procedures associated with it have been fully explained to me. I have had 
the opportunity to ask questions concerning any and all aspects of the project and the procedures 
involved.  I am aware that participation is voluntary and that I may withdraw my consent at any time. 
Confidentiality of records concerning my involvement in this project will be maintained in an 
appropriate manner.  When required by law, the records of this research may be reviewed by 
government agencies and sponsors of the research. 
I understand that the sponsors and investigators have such insurance as is required by law in the event 
of injury resulting from this research. 
I, the undersigned, hereby consent to participate as a subject in the above described project 
conducted at the Cork Teaching Hospitals.  I have received a copy of this consent form for my records.  
I understand that if I have any questions concerning this research, I can contact the doctor(s) listed 
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above.  If I have further queries concerning my rights in connection with the research, I can contact 
the Clinical Research Ethics Committee of the Cork Teaching Hospitals, Lancaster Hall, 6 Little Hanover 
Street, Cork. 
After reading the entire consent form, if you have no further questions about giving consent, please 
sign where indicated. 
 
 
 
Signature of doctor:____________________________________________ 
 
 
Signature of subject:____________________________________________  
  
         
     
 
Date:                             Time:      AM     PM (Circle) 
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GP Consent form for participation in research study 
 
Study title: PHARMS (Patient Held Active Record of Medication Status) Study 
You are being invited to take part in a research study which is being conducted at the University 
College Cork and the Mercy University Hospital.  
Before you decide whether or not you wish to participate you should read the information provided 
below. You should clearly understand the risks and benefits of participating in this study. Take time 
to ask questions – do not feel rushed or under any obligation to make a hasty judgment. 
You are not obliged to take part in this study. You have the right to withdraw your participation at 
any time (before, during and after the study) for whatever reason without having to justify your 
decision and without negative impact.  
Why is this study being conducted? 
Medication errors frequently occur during transitional care as patients move between different 
stages and settings of care. Hospital discharge has been identified as a time where medication error 
is likely to occur with negative consequences for the patient, GP and community pharmacist. 
Providing junior doctors with a list of medication taken by a patient pre hospital admission may help 
to reduce error when they generating discharge medication information.  The GP has been identified 
as an accurate provider of such medication information. Transferring medication information 
between primary and secondary care is challenging. As a potential solution to the problem a patient 
held electronic medication record has been developed within UCC and is now ready to be tested in 
the clinical setting. This device resembles a key and utilizes the USB port of a computer-see image. 
The master medication list may only be modified by you the patient’s GP but changes to the 
patient’s medication may be added to the record in the hospital setting. 
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What will your participation involve? 
Eligible patients will be issued with a device during their inpatient stay in the Mercy University 
Hospital. You will be required to link the device to the patient’s record when it is brought to the 
practice by the investigator. The intern will then be able to view the medication list of your patient 
as it appears in your record when they are generating the discharge prescription.  The intern will 
note any adjustments made to the patient’s medication during the hospital stay. These adjustments 
will be communicated to you via a note which will appear in the patient’s file. Changes to the 
patient’s medication list can only be made by you.  
You will also be required to participate in an interview which will explore your experience of using 
the device.  
Confidentiality 
The interview will be treated in a confidential manner and your participation is anonymous. The 
interview will be audio recorded so that it can be transcribed afterwards. Your name will not be 
recorded on any information which is collected about you. Instead you will be provided with a 
unique code. The only person with access to the code will be the investigator. The study results and 
anonymized excerpts from your interview may be presented at scientific conferences and/or 
published in an academic journal.  The audio recording will be erased once the interview has been 
transcribed. Transcripts will be stored for 5 years; after which they will be destroyed in line with 
Data Protection legislation. 
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What are the possible benefits of participating? 
You may find that having an up to date record of a patient’s medication immediately following 
discharge is helpful in their management. Errors and omissions on hospital discharge prescriptions 
result in considerable work load in general practice and using an electronic patient held medication 
record may potentially firstly reduce the occurrence of patient harm and secondly reduce general 
practitioner work load. 
Are there any risks of participation? 
It is hoped that no significant negative impact will arise from the study. There is the potential that 
using this device may add to your work load. The investigator will ensure that linking the device to 
the patient’s record takes place at a time that is convenient for you. Additionally, due to the small 
numbers of patients that are involved and the involvement of 3 general practices it is hoped that 
work load will not be an issue.  If difficulties arise the investigator is available to be contacted. 
Further information 
A copy of the interview transcript and study results can be made available to you. 
If you need any further information, do not hesitate to contact the investigator Dr Elaine Walsh, 
Department of General Practice UCC, elaine.walsh@ucc.ie 
Thank you for taking the time to read this information sheet. If you agree to take part in the study, 
please sign the consent form  
 
I ______________________ declare that information regarding this study had been given to me and 
I understand the purpose, methods, risks and benefits of participating in this study. 
I am aware that participation is voluntary and that I can withdraw my participation at any time 
without negative impact.  
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I give permission for my responses in the interview to be audio-recorded. I understand that my 
anonymity will be guaranteed.  
I understand that anonymized extracts from my interview may be quoted in a publication arising 
from this study.   
I agree that I have received a copy of this Consent Form and a copy of the Information Letter. 
I hereby give my informed consent to participate in the research study. 
 
 
Participant Signature                                   Date 
_______________________________________________                            ______________________ 
Signature of investigator                                                                                         Date 
 
Would you like a copy of the Interview Transcript?                  YES              NO    
 
Do you want a copy of the findings after the study is completed?   YES               NO    
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Junior doctor consent form for participation in research study 
Study title: PHARMS (Patient Held Active Record of Medication Status) Study 
You are being invited to take part in a research study which is being conducted at the University 
College Cork.  
Before you decide whether or not you wish to participate you should read the information provided 
below. You should clearly understand the risks and benefits of participating in this study. Take time 
to ask questions – do not feel rushed or under any obligation to make a hasty judgment. 
You are not obliged to take part in this study and if you decide not to participate this will have no 
effect on your training or evaluation.  
You have the right to withdraw your participation at any time (before, during and after the study) for 
whatever reason without having to justify your decision and without negative impact.  
Why is this study being conducted? 
Medication errors frequently occur during transitional care as patients move between different 
stages and settings of care. Hospital discharge has been identified as a time where medication error 
is likely to occur. Having a patient’s pre-admission medication list available at time of hospital 
discharge may help in reducing error when generating discharge medication information. 
Additionally, evidence suggests that an electronic record may improve prescribing at time of 
discharge. A patient held electronic medication record has been developed within UCC and is now 
ready to be tested in the clinical setting. This device utilizes the USB port of a computer-see attached 
image. The master medication list may only be modified by the patient’s GP but changes to the 
patient’s medication may be added to the record in the hospital setting. 
What will your participation involve? 
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You will be required to use the patient held medication record when writing the discharge 
prescription of study participants. You will be required to access the electronic medication record on 
the computer on the ward and to enter any adjustments, additions or cessations of medication that 
occurred during the hospital stay.  
You will also be required to participate in an interview which will explore your experience of using 
the device.  
Confidentiality 
The interview will be treated in a confidential manner and your participation is anonymous. The 
interview will be audio recorded so that it can be transcribed afterwards. Your name will not be 
recorded on any information which is collected about you. Instead you will be provided with a 
unique code. The only person with access to the code will be the investigator. The study results and 
anonymized excerpts from your interview may be presented at scientific conferences and/or 
published in an academic journal.  The audio recording will be erased once the interview has been 
transcribed. Transcripts will be stored for 5 years; after which they will be destroyed in line with 
Data protection legislation. 
What are the possible benefits of participating? 
You may find that having an up to date record of a patient’s pre-admission medication list is helpful 
when generating their discharge prescription. From a societal perspective there is the potential that 
using an electronic patient held medication record may reduce the occurrence of patient harm via 
amelioration of the discharge prescribing process with the net result of reducing morbidity, 
mortality and economic burden. 
Are there any risks of participation? 
We do not think that participation in this study will have any negative effect on you. However, if 
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utilization of the device or the interview regarding same causes you difficulty or concern your intern 
tutor or the investigator may be contacted. 
Further information 
A copy of the interview transcript and study results can be made available to you. 
If you need any further information, do not hesitate to contact the investigator Dr Elaine Walsh, 
Department of General Practice UCC, elaine.walsh@ucc.ie 
Thank you for taking the time to read this information sheet. If you agree to take part in the study, 
please sign the consent form 
I ______________________ declare that information regarding this study had been given to me and 
I understand the purpose, methods, risks and benefits of participating in this study. 
I am aware that participation is voluntary and that I can withdraw my participation at any time 
without negative impact.  
I give permission for my responses in the interview to be audio-recorded. I understand that my 
anonymity will be guaranteed.  
I understand that anonymized extracts from my interview may be quoted in a publication arising 
from this study.   
I agree that I have received a copy of this Consent Form and a copy of the Information Letter. 
I hereby give my informed consent to participate in the research study. 
 
 
Participant Signature                                   Date 
_______________________________________________                            ______________________ 
Signature of investigator                                                                                         Date 
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Would you like a copy of the Interview Transcript?                  YES              NO    
 
Do you want a copy of the findings after the study is completed?   YES               NO    
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Topic guides for interviews 
 
Topic guide for semi-structured interviews with junior doctors: 
 
1. Experience of using the device  
2. Usefulness of the device 
3. Difficulties encountered with the device 
4. Recommendations for modification of the device 
5. Communication with primary care 
 
Topic guide for semi-structured interviews with IT professionals: 
 
1. Experience of use of the device 
2. Experience of integration of the device into the existing IT system 
3. Difficulties encountered with the device 
4. Recommendations for modification of the device 
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Topic guide for semi-structured interviews with GPs: 
 
1. Experience of using the device  
2. Usefulness of the device 
3. Difficulties encountered with the device 
4. Recommendations for modification of the device 
5. Communication with secondary care 
 
Topic guide for semi-structured interviews with patients: 
 
1. Experience of using the device  
2. Usefulness of the device 
3. Difficulties encountered with the device 
4. Acceptability of the device and technology 
5. Recommendations for modification of the device 
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Clinical Significance of errors: instructions for raters 
 
Definition: this is the degree of patient harm that could be caused by the error. 
Significant: an error that can cause patient symptoms that, while harmful to the patient, poses little 
or no threat to the patient’s life function. 
Serious: an error than can cause signs/ symptoms that are associated with a serious level of risk that 
is not high enough to be life-threatening. In addition, a potential ADE is serious if it can cause 
persistent alteration of daily function. 
Life-threatening: an error that can cause signs/symptoms that if not treated would put the patient 
at risk of death. 
Examples of Severity Categories 
LIFE THREATENING 
Incorrect dose of anti-rejection medication is prescribed in patient with kidney transplant. 
Omission of amiodarone at discharge when given for prevention of ventricular tachycardia. 
Patient with a prior penicillin anaphylaxis reaction and ordered penicillin at admission. 
Incorrect paracetamol dose prescribed at discharge with a total daily dose >15g. 
Omission of warfarin at admission in patient with mitral valve replacement. 
SERIOUS 
Patients’ correct dose is 2 mg diazepam; doctor prescribes 10 mg on admission. 
Patient with exacerbation of congestive cardiac failure discharged on 1/4 preadmission dose of 
frusemide. 
Omission of beta-blocker at discharge in patient with coronary artery disease. 
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Concurrent paracetamol prescriptions at discharge with a total daily dose >10g but ≤15g. 
Warfarin 5 mg QD prescribed at discharge instead of 3 mg QD (prescribed for atrial fibrillation). 
Indomethacin for gout prescribed at discharge to patient concurrently taking Ibuprofen. 
Omission of lactulose BD in patient with history of hepatic encephalopathy. 
SIGNIFICANT 
Omission of diazepam PRN for insomnia at discharge. 
Change from laxative bisocodyl PRN to bisocodyl BD 
Omission of lisinopril in patient without coronary artery disease, heart failure or valve disease. 
Two concurrent paracetamol prescriptions with a total daily dose >4 grams but ≤10 grams. 
Omission of tramadol PRN for tension headache. 
Additional Examples 
Errors that may lead to hypotension or over-treatment of hypertension are considered to be serious. 
Errors that may lead to under-treatment of hypertension, angina, or ischemia are considered to be 
significant. 
Errors that may lead to significant over-anticoagulation or under-coagulation are considered to be 
serious. 
Errors that lead to under-treatment of asthma are considered to be significant. 
Errors that lead to under-treatment with antibiotics: 
 If IV antibiotics were originally prescribed, consider the errors to be serious. 
 If oral antibiotics were originally prescribed, consider the errors to be significant. 
Errors that lead to over-treatment with antibiotics: 
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 If either IV or oral antibiotics were prescribed, consider the errors to be significant, unless 
the antibiotic is directly toxic to end organs in a highly dose-sensitive fashion (e.g., 
gentamicin), in which case, the severity will be higher (usually serious). 
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CONSORT 2010 checklist: information to include when reporting a pilot or feasibility trial  
 
Table A3 1: CONSORT checklist 
 
Section/Topic 
Ite
m 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a pilot or feasibility randomised trial in the title 96 
1b Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see 
CONSORT abstract extension for pilot trials) 
97,98 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale for future definitive trial, and reasons for randomised 
pilot trial 
99-103 
2b Specific objectives or research questions for pilot trial 103 
Methods 
Trial design 3a Description of pilot trial design (such as parallel, factorial) including allocation ratio 1104,105 
3b Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 105 
4b Settings and locations where the data were collected 105 
 4c How participants were identified and consented 105 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they 
were actually administered 
105 
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Outcomes 6a Completely defined prespecified assessments or measurements to address each pilot trial objective 
specified in 2b, including how and when they were assessed 
106 
6b Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons N/A 
 6c If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial N/A 
Sample size 7a Rationale for numbers in the pilot trial 104,105 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
Sequence  
generation 
8a Method used to generate the random allocation sequence N/A 
8b Type of randomisation(s); details of any restriction (such as blocking and block size) N/A 
Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered 
containers), describing any steps taken to conceal the sequence until interventions were assigned 
N/A 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants 
to interventions 
N/A 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
N/A 
11b If relevant, description of the similarity of interventions N/A 
Statistical 
methods 
12 Methods used to address each pilot trial objective whether qualitative or quantitative 107-110 
Results 
Participant flow (a 
diagram is 
13a For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly 
assigned, received intended treatment, and were assessed for each objective 
111 
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strongly 
recommended) 
13b For each group, losses and exclusions after randomisation, together with reasons 111 
Recruitment 14a Dates defining the periods of recruitment and follow-up 104 
14b Why the pilot trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 112 
Numbers 
analysed 
16 For each objective, number of participants (denominator) included in each analysis. If relevant, these 
numbers 
should be by randomised group 
112 
Outcomes and 
estimation 
17 For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any 
estimates. If relevant, these results should be by randomised group 
114 
Ancillary analyses 18 Results of any other analyses performed that could be used to inform the future definitive trial 112-124 
Harms 19 All-important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A 
 19a If relevant, other important unintended consequences N/A 
Discussion 
Limitations 20 Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility 125,126 
Generalisability 21 Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies 128 
Interpretation 22 Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and 
considering other relevant evidence 
126-128 
 22a Implications for progression from pilot to future definitive trial, including any proposed amendments 128,129 
Other information 
 
Registration 23 Registration number for pilot trial and name of trial registry N/A 
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Protocol 24 Where the pilot trial protocol can be accessed, if available 223 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 14 
 26 Ethical approval or approval by research review committee, confirmed with reference number 79 
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Data collection form 
 
 
Study ID Medication Dose  Frequency GP Pharmacy Drug chart Discharge prescription Error description Error number Error score 
           
           
           
           
           
           
           
           
           
           
           
Study ID Age Gender SES Length of stay  Medication number at 
admission 
Continence Mobility Feeding Dressing 
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Policy brief 
 
 
 
PHARMS: Patient Held Active Record of Medication Status Policy 
Brief 
Prepared by Elaine Walsh  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Executive summary 
 
Medication error as patients move between hospital and the community is 
an important patient safety issue. Poor communication of medication 
information between primary and secondary care is currently an issue 
within the Irish healthcare system. The PHARMS device is a patient held 
electronic medication record which uses basic USB technology. The device 
has been shown to be acceptable to patients, doctors and IT professionals. 
It can successfully integrate into existing electronic systems in both primary 
and secondary care without the need for significant investment. It has been 
shown to reduce medication error at time of hospital discharge.  
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Introduction 
Though in excess of 90% of Irish GPs operate electronic healthcare records (EHR), a mix of paper and 
electronic records are currently used in Irish hospitals. Communication of patient information 
between primary and secondary care is problematic. Poor communication of medication information 
is a major source of medication error resulting in patient morbidity, mortality and economic burden.  
 
Methods 
A patient held medication record was developed using USB technology and a thorough initial 
evaluation was conducted using quantitative and qualitative methods. 
 
Findings 
GPs, patients and junior doctors all described the occurrence of, and difficulties with, medication 
error and poor communication of medication information within the existing system. 
 
 
 
 
  
 
 
 
 
 
 
 
 
We forever have people coming in 
who are missing things for a week 
until someone discovers they’re 
missing whatever” 
And in some cases then you have to follow up 
with the hospital and following up with the 
hospital is incredibly time-consuming.  Like, 
really incredibly time-consuming and frustrating 
and annoying. I mean, I can’t be strong enough 
on how, what a waste of time it is. 
I remember like one day coming out and the 
nurse had to ring the doctor to query something 
because the inhaler they had given me shouldn’t 
be given with the medications I was on 
Junior doctor 
                       GP 
             Patient 
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Medication information was successfully transferred between primary and secondary care via the 
PHARMS device. Compatibility was demonstrated with the four accredited GP software systems in 
Ireland: Socrates, CompleteGP, Health One, Helix Practice Manager. Successful integration was 
demonstrated within a basic existing IT hospital system. 
Statistically significant lower rates of clinically significant medication errors were found among 
patient who were issued with a PHARMS device.  
The device was acceptable to patients, GPs and hospital doctors. 
 
 
 
 
 
 
Recommendations 
 
 In technology terms a “minimum viable product” is a basic product solving a core problem. 
With regard to medication error as patients move between hospital and the community, the 
PHARMS device could be a solution to a core problem.  
 Implementation the EHR in Ireland has not been straightforward and a universal shared care 
record does not yet exist. The PHARMS device can be used successfully within existing GP 
and hospital systems without significant additional IT investment and therefore may be 
complementary to ongoing shared care record development.  
 Though more advanced technologies than USB exist, such technologies may not be 
applicable to the Irish healthcare system 
 Well it’s very handy so your GP would have it and [you,] 
when you go to hospital all your information is on it, it’s 
brilliant 
             Patient 
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